NO20001687L - Benzamidinderivater som faktor Xa-inhibitorer - Google Patents
Benzamidinderivater som faktor Xa-inhibitorerInfo
- Publication number
- NO20001687L NO20001687L NO20001687A NO20001687A NO20001687L NO 20001687 L NO20001687 L NO 20001687L NO 20001687 A NO20001687 A NO 20001687A NO 20001687 A NO20001687 A NO 20001687A NO 20001687 L NO20001687 L NO 20001687L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- piperazine
- methyl
- phenyl
- fab
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 150000003937 benzamidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 108
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 25
- 125000006239 protecting group Chemical group 0.000 claims description 20
- 239000000460 chlorine Substances 0.000 claims description 19
- 229910052731 fluorine Inorganic materials 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 229910052801 chlorine Inorganic materials 0.000 claims description 18
- 125000001624 naphthyl group Chemical group 0.000 claims description 18
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 229910052740 iodine Inorganic materials 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 108010074860 Factor Xa Proteins 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 125000004434 sulfur atom Chemical group 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 238000002399 angioplasty Methods 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 206010022562 Intermittent claudication Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- BQKNCYMMOGNLIE-UHFFFAOYSA-N 4-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazine-1-carbonyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1 BQKNCYMMOGNLIE-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 150000004866 oxadiazoles Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- YMWCJRQRFNLRPO-UHFFFAOYSA-N 4-[4-(2-phenylethenylsulfonyl)piperazine-1-carbonyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N1CCN(S(=O)(=O)C=CC=2C=CC=CC=2)CC1 YMWCJRQRFNLRPO-UHFFFAOYSA-N 0.000 claims 1
- MZSKTABWYFLIPP-UHFFFAOYSA-N 4-[4-(3-amino-4-chlorophenyl)sulfonylpiperazine-1-carbonyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N1CCN(S(=O)(=O)C=2C=C(N)C(Cl)=CC=2)CC1 MZSKTABWYFLIPP-UHFFFAOYSA-N 0.000 claims 1
- IVDPHPQQNGBSTH-UHFFFAOYSA-N 4-[4-(4-propylphenyl)sulfonylpiperazine-1-carbonyl]benzenecarboximidamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C(N)=N)CC1 IVDPHPQQNGBSTH-UHFFFAOYSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- -1 Aromatic amidine Chemical class 0.000 description 243
- 238000006243 chemical reaction Methods 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 238000005984 hydrogenation reaction Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000010626 work up procedure Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000012442 inert solvent Substances 0.000 description 9
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 8
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 150000001409 amidines Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 235000011054 acetic acid Nutrition 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- LEFGAGRZHLNPLS-UHFFFAOYSA-N 4-propylbenzenesulfonyl chloride Chemical compound CCCC1=CC=C(S(Cl)(=O)=O)C=C1 LEFGAGRZHLNPLS-UHFFFAOYSA-N 0.000 description 5
- IYFIYGSJZIICOZ-UHFFFAOYSA-N 6-chloronaphthalene-2-sulfonyl chloride Chemical compound C1=C(S(Cl)(=O)=O)C=CC2=CC(Cl)=CC=C21 IYFIYGSJZIICOZ-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 230000009424 thromboembolic effect Effects 0.000 description 5
- 230000007306 turnover Effects 0.000 description 5
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
- XKDBKBMAWNBNRE-UHFFFAOYSA-N [amino(phenyl)methylidene]azanium;acetate Chemical compound CC(O)=O.NC(=N)C1=CC=CC=C1 XKDBKBMAWNBNRE-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- ZHEYVXCFYIWQOM-UHFFFAOYSA-N 6-chloronaphthalene-1-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC2=CC(Cl)=CC=C21 ZHEYVXCFYIWQOM-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- OPECTNGATDYLSS-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21 OPECTNGATDYLSS-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- RSJSYCZYQNJQPY-UHFFFAOYSA-N 3,4-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1OC RSJSYCZYQNJQPY-UHFFFAOYSA-N 0.000 description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- DTKAUYQBZSOHRJ-UHFFFAOYSA-N 4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoic acid Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(O)=O)=N1 DTKAUYQBZSOHRJ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- CSGQUTFMONBCSR-UHFFFAOYSA-N [3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-piperazin-1-ylmethanone Chemical compound O1C(C)=NC(C=2C=C(C=CC=2)C(=O)N2CCNCC2)=N1 CSGQUTFMONBCSR-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- WCKKWABZCCKDTN-UHFFFAOYSA-N decane-1-sulfonyl chloride Chemical compound CCCCCCCCCCS(Cl)(=O)=O WCKKWABZCCKDTN-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- DASJFYAPNPUBGG-UHFFFAOYSA-N naphthalene-1-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CC=CC2=C1 DASJFYAPNPUBGG-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- CFNMHCWDZSUUQI-UHFFFAOYSA-N (2-methyl-5-nitrophenyl)methanesulfonyl chloride Chemical compound CC1=CC=C([N+]([O-])=O)C=C1CS(Cl)(=O)=O CFNMHCWDZSUUQI-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JUSWZYFYLXTMLJ-JTQLQIEISA-N (2s)-1-(benzenesulfonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=CC=C1 JUSWZYFYLXTMLJ-JTQLQIEISA-N 0.000 description 1
- RQYKQWFHJOBBAO-JTQLQIEISA-N (2s)-1-benzoylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)C1=CC=CC=C1 RQYKQWFHJOBBAO-JTQLQIEISA-N 0.000 description 1
- YRAYVSQKHFMWKM-UHFFFAOYSA-N (4-benzylsulfonylpiperazin-1-yl)-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)CC=2C=CC=CC=2)=N1 YRAYVSQKHFMWKM-UHFFFAOYSA-N 0.000 description 1
- BDKYWVUHHLJYDF-UHFFFAOYSA-N (4-decylsulfonylpiperazin-1-yl)-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound C1CN(S(=O)(=O)CCCCCCCCCC)CCN1C(=O)C1=CC=C(C=2N=C(C)ON=2)C=C1 BDKYWVUHHLJYDF-UHFFFAOYSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- ZRSGZIMDIHBXIN-UHFFFAOYSA-N 1,3-benzodioxole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2OCOC2=C1 ZRSGZIMDIHBXIN-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- OMLXLSWPGNPGPU-UHFFFAOYSA-N 1-(2,4,6-trimethylphenyl)sulfonylpiperazine Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)N1CCNCC1 OMLXLSWPGNPGPU-UHFFFAOYSA-N 0.000 description 1
- RKZQNDSKKYMCBA-UHFFFAOYSA-N 1-(2-phenylethenylsulfonyl)piperazine Chemical compound C1CNCCN1S(=O)(=O)C=CC1=CC=CC=C1 RKZQNDSKKYMCBA-UHFFFAOYSA-N 0.000 description 1
- AMFSRRVNNJMVEJ-UHFFFAOYSA-N 1-(4-benzylsulfonylpiperazin-1-yl)-2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]ethanone Chemical compound O1C(C)=NC(C=2C=CC(CC(=O)N3CCN(CC3)S(=O)(=O)CC=3C=CC=CC=3)=CC=2)=N1 AMFSRRVNNJMVEJ-UHFFFAOYSA-N 0.000 description 1
- CKVKEBVACPUEIB-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonylpiperazine Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1CCNCC1 CKVKEBVACPUEIB-UHFFFAOYSA-N 0.000 description 1
- GORMTLXDLRUYIT-UHFFFAOYSA-N 1-(4-decylsulfonylpiperazin-1-yl)-2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]ethanone Chemical compound C1CN(S(=O)(=O)CCCCCCCCCC)CCN1C(=O)CC1=CC=C(C=2N=C(C)ON=2)C=C1 GORMTLXDLRUYIT-UHFFFAOYSA-N 0.000 description 1
- UJGNXLDOTDJYGH-UHFFFAOYSA-N 1-(4-propylphenyl)sulfonylpiperazine Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCNCC1 UJGNXLDOTDJYGH-UHFFFAOYSA-N 0.000 description 1
- FMLPGZYYCBFFLU-UHFFFAOYSA-N 1-(6-chloronaphthalen-2-yl)sulfonylpiperazine Chemical compound C1=CC2=CC(Cl)=CC=C2C=C1S(=O)(=O)N1CCNCC1 FMLPGZYYCBFFLU-UHFFFAOYSA-N 0.000 description 1
- CCAWDIFJOBKBSE-UHFFFAOYSA-N 1-(chloromethyl)-3,5-dimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1 CCAWDIFJOBKBSE-UHFFFAOYSA-N 0.000 description 1
- MEPBLENVCZDFNJ-UHFFFAOYSA-N 1-[4-(2,1,3-benzothiadiazol-4-ylsulfonyl)piperazin-1-yl]-2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]ethanone Chemical compound O1C(C)=NC(C=2C=CC(CC(=O)N3CCN(CC3)S(=O)(=O)C=3C4=NSN=C4C=CC=3)=CC=2)=N1 MEPBLENVCZDFNJ-UHFFFAOYSA-N 0.000 description 1
- FKOCEPBYEMPNOO-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)sulfonylpiperazin-1-yl]-2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]ethanone Chemical compound O1C(C)=NC(C=2C=CC(CC(=O)N3CCN(CC3)S(=O)(=O)C=3C=C(Cl)C(Cl)=CC=3)=CC=2)=N1 FKOCEPBYEMPNOO-UHFFFAOYSA-N 0.000 description 1
- YFLDOMARCHZTIV-UHFFFAOYSA-N 1-[4-(3,4-dimethoxyphenyl)sulfonylpiperazin-1-yl]-2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]ethanone Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N1CCN(C(=O)CC=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 YFLDOMARCHZTIV-UHFFFAOYSA-N 0.000 description 1
- RGVFXCOITFAXIV-UHFFFAOYSA-N 1-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazin-1-yl]-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]propan-1-one Chemical compound O1C(C)=NC(C=2C=CC(CCC(=O)N3CCN(CC3)S(=O)(=O)C=3C=C4C=CC(Cl)=CC4=CC=3)=CC=2)=N1 RGVFXCOITFAXIV-UHFFFAOYSA-N 0.000 description 1
- OQBNZUOWINHNTN-UHFFFAOYSA-N 1-[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]-2-phenoxyethanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)COC=2C=CC=CC=2)=N1 OQBNZUOWINHNTN-UHFFFAOYSA-N 0.000 description 1
- DNGLRCHMGDDHNC-UHFFFAOYSA-N 1-benzothiophene-2-carbonyl chloride Chemical compound C1=CC=C2SC(C(=O)Cl)=CC2=C1 DNGLRCHMGDDHNC-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- QZTWVDCKDWZCLV-UHFFFAOYSA-N 1-isocyanato-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(N=C=O)C=C1 QZTWVDCKDWZCLV-UHFFFAOYSA-N 0.000 description 1
- FMDGXCSMDZMDHZ-UHFFFAOYSA-N 1-isocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1 FMDGXCSMDZMDHZ-UHFFFAOYSA-N 0.000 description 1
- GFNKTLQTQSALEJ-UHFFFAOYSA-N 1-isocyanato-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(N=C=O)C=C1 GFNKTLQTQSALEJ-UHFFFAOYSA-N 0.000 description 1
- BDQNKCYCTYYMAA-UHFFFAOYSA-N 1-isocyanatonaphthalene Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1 BDQNKCYCTYYMAA-UHFFFAOYSA-N 0.000 description 1
- OJWPAXRMRPPQBG-UHFFFAOYSA-N 1-naphthalen-2-ylsulfonylpiperazine Chemical compound C=1C=C2C=CC=CC2=CC=1S(=O)(=O)N1CCNCC1 OJWPAXRMRPPQBG-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CXAICGCTHOWKPP-UHFFFAOYSA-N 2,1,3-benzothiadiazole-4-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC2=NSN=C12 CXAICGCTHOWKPP-UHFFFAOYSA-N 0.000 description 1
- PQODWTNHDKDHIW-UHFFFAOYSA-N 2,3-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1Cl PQODWTNHDKDHIW-UHFFFAOYSA-N 0.000 description 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 1
- PVJZBZSCGJAWNG-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonyl chloride Chemical compound CC1=CC(C)=C(S(Cl)(=O)=O)C(C)=C1 PVJZBZSCGJAWNG-UHFFFAOYSA-N 0.000 description 1
- BXCOSWRSIISQSL-UHFFFAOYSA-N 2,5-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(Cl)C(S(Cl)(=O)=O)=C1 BXCOSWRSIISQSL-UHFFFAOYSA-N 0.000 description 1
- GCXPJRMNDARTJW-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)-1-[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]ethanone Chemical compound COC1=CC=C(OC)C(CC(=O)N2CCN(CC2)C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)=C1 GCXPJRMNDARTJW-UHFFFAOYSA-N 0.000 description 1
- RAPIPBRHRYSAHQ-UHFFFAOYSA-N 2-(2,5-dimethoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(OC)C(CC(Cl)=O)=C1 RAPIPBRHRYSAHQ-UHFFFAOYSA-N 0.000 description 1
- ICMYBXSQADZKHQ-UHFFFAOYSA-N 2-(4-carbamimidoyl-n-(4-naphthalen-2-ylsulfonylpiperazine-1-carbonyl)anilino)acetic acid Chemical compound C1=CC(C(=N)N)=CC=C1N(CC(O)=O)C(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 ICMYBXSQADZKHQ-UHFFFAOYSA-N 0.000 description 1
- SYYUMMQQTQFEJF-UHFFFAOYSA-N 2-(4-carbamimidoyl-n-[4-(2-phenylethenylsulfonyl)piperazine-1-carbonyl]anilino)acetic acid Chemical compound C1=CC(C(=N)N)=CC=C1N(CC(O)=O)C(=O)N1CCN(S(=O)(=O)C=CC=2C=CC=CC=2)CC1 SYYUMMQQTQFEJF-UHFFFAOYSA-N 0.000 description 1
- GNKMRAUHEGDXLE-UHFFFAOYSA-N 2-(4-carbamimidoyl-n-[4-(4-phenylphenyl)sulfonylpiperazine-1-carbonyl]anilino)acetic acid Chemical compound C1=CC(C(=N)N)=CC=C1N(CC(O)=O)C(=O)N1CCN(S(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 GNKMRAUHEGDXLE-UHFFFAOYSA-N 0.000 description 1
- MMUJRDIBPXQPDD-UHFFFAOYSA-N 2-(4-carbamimidoyl-n-[4-(4-propylphenyl)sulfonylpiperazine-1-carbonyl]anilino)acetic acid Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)N(CC(O)=O)C=2C=CC(=CC=2)C(N)=N)CC1 MMUJRDIBPXQPDD-UHFFFAOYSA-N 0.000 description 1
- DLPNIJAEZDNGCV-UHFFFAOYSA-N 2-(4-carbamimidoyl-n-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazine-1-carbonyl]anilino)acetic acid Chemical compound C1=CC(C(=N)N)=CC=C1N(CC(O)=O)C(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1 DLPNIJAEZDNGCV-UHFFFAOYSA-N 0.000 description 1
- JNDSOWJSURFZPP-UHFFFAOYSA-N 2-(4-carbamimidoylphenyl)-4-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)-4-oxobutanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1C(C(O)=O)CC(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 JNDSOWJSURFZPP-UHFFFAOYSA-N 0.000 description 1
- GVNJJBBLTHAVGZ-UHFFFAOYSA-N 2-(4-carbamimidoylphenyl)-4-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazin-1-yl]-4-oxobutanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1C(C(O)=O)CC(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1 GVNJJBBLTHAVGZ-UHFFFAOYSA-N 0.000 description 1
- BTVSPJDDFCJXBO-UHFFFAOYSA-N 2-(4-carbamimidoylphenyl)-4-oxo-4-[4-(2-phenylethenylsulfonyl)piperazin-1-yl]butanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1C(C(O)=O)CC(=O)N1CCN(S(=O)(=O)C=CC=2C=CC=CC=2)CC1 BTVSPJDDFCJXBO-UHFFFAOYSA-N 0.000 description 1
- BZGQNIWAQFBYRN-UHFFFAOYSA-N 2-(4-carbamimidoylphenyl)-4-oxo-4-[4-(4-phenylphenyl)sulfonylpiperazin-1-yl]butanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1C(C(O)=O)CC(=O)N1CCN(S(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 BZGQNIWAQFBYRN-UHFFFAOYSA-N 0.000 description 1
- RQPYMPWPCHFLDY-UHFFFAOYSA-N 2-(4-carbamimidoylphenyl)-4-oxo-4-[4-(4-propylphenyl)sulfonylpiperazin-1-yl]butanoic acid Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)CC(C(O)=O)C=2C=CC(=CC=2)C(N)=N)CC1 RQPYMPWPCHFLDY-UHFFFAOYSA-N 0.000 description 1
- DSZXHLVPFXHBFK-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]ethanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)CC=2C=CC(Cl)=CC=2)=N1 DSZXHLVPFXHBFK-UHFFFAOYSA-N 0.000 description 1
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 1
- MPCHQYWZAVTABQ-UHFFFAOYSA-N 2-(chloromethyl)naphthalene Chemical compound C1=CC=CC2=CC(CCl)=CC=C21 MPCHQYWZAVTABQ-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- ZNBQLRSWJYQMES-UHFFFAOYSA-N 2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(4-naphthalen-1-ylsulfonylpiperazin-1-yl)ethanone Chemical compound O1C(C)=NC(C=2C=CC(CC(=O)N3CCN(CC3)S(=O)(=O)C=3C4=CC=CC=C4C=CC=3)=CC=2)=N1 ZNBQLRSWJYQMES-UHFFFAOYSA-N 0.000 description 1
- ZKPUHQFROWHGPC-UHFFFAOYSA-N 2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)ethanone Chemical compound O1C(C)=NC(C=2C=CC(CC(=O)N3CCN(CC3)S(=O)(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 ZKPUHQFROWHGPC-UHFFFAOYSA-N 0.000 description 1
- BNEUDWYUCWESGY-UHFFFAOYSA-N 2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(4-propan-2-ylsulfonylpiperazin-1-yl)ethanone Chemical compound C1CN(S(=O)(=O)C(C)C)CCN1C(=O)CC1=CC=C(C=2N=C(C)ON=2)C=C1 BNEUDWYUCWESGY-UHFFFAOYSA-N 0.000 description 1
- PLYONGSRFNFPEF-UHFFFAOYSA-N 2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-[4-(2,4,6-trimethylphenyl)sulfonylpiperazin-1-yl]ethanone 2,4,6-trimethylbenzenesulfonyl chloride Chemical compound Cc1cc(C)c(c(C)c1)S(Cl)(=O)=O.Cc1nc(no1)-c1ccc(CC(=O)N2CCN(CC2)S(=O)(=O)c2c(C)cc(C)cc2C)cc1 PLYONGSRFNFPEF-UHFFFAOYSA-N 0.000 description 1
- DVWGZDDMSSNEIM-UHFFFAOYSA-N 2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-[4-(4-propylphenyl)sulfonylpiperazin-1-yl]ethanone Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)CC=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 DVWGZDDMSSNEIM-UHFFFAOYSA-N 0.000 description 1
- SRUOVCPOBZBHMG-UHFFFAOYSA-N 2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-piperazin-1-ylethanone Chemical compound O1C(C)=NC(C=2C=CC(CC(=O)N3CCNCC3)=CC=2)=N1 SRUOVCPOBZBHMG-UHFFFAOYSA-N 0.000 description 1
- SCQAUEYGYGFQIQ-UHFFFAOYSA-N 2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]acetic acid Chemical compound O1C(C)=NC(C=2C=CC(CC(O)=O)=CC=2)=N1 SCQAUEYGYGFQIQ-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BJYNYQGJTZULJI-UHFFFAOYSA-N 2-methoxy-5-methylbenzenesulfonyl chloride Chemical compound COC1=CC=C(C)C=C1S(Cl)(=O)=O BJYNYQGJTZULJI-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- PEVFJTMXKKADBR-UHFFFAOYSA-N 2-methylpropyl 4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC(C)C)CCN1C(=O)C1=CC=C(C=2N=C(C)ON=2)C=C1 PEVFJTMXKKADBR-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- PKUPAJQAJXVUEK-UHFFFAOYSA-N 2-phenoxyacetyl chloride Chemical compound ClC(=O)COC1=CC=CC=C1 PKUPAJQAJXVUEK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- NYIBPWGZGSXURD-UHFFFAOYSA-N 3,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1Cl NYIBPWGZGSXURD-UHFFFAOYSA-N 0.000 description 1
- SHNFSARCTLLYMS-UHFFFAOYSA-N 3,4-dichlorobenzenesulfonyl chloride;[4-(3,4-dichlorophenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1Cl.O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2)=N1 SHNFSARCTLLYMS-UHFFFAOYSA-N 0.000 description 1
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 1
- FSGLUBQENACWCC-UHFFFAOYSA-N 3,4-difluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1F FSGLUBQENACWCC-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- GZLPFEYTAAXJCP-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole-4-sulfonyl chloride Chemical compound CC1=NOC(C)=C1S(Cl)(=O)=O GZLPFEYTAAXJCP-UHFFFAOYSA-N 0.000 description 1
- MIFHXAPYMFWFCP-UHFFFAOYSA-N 3-(4-isocyanatophenyl)-5-methyl-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)N=C=O)=N1 MIFHXAPYMFWFCP-UHFFFAOYSA-N 0.000 description 1
- LXGJRZCNBSCWHV-UHFFFAOYSA-N 3-[4-(4-butylsulfonylpiperazin-1-yl)phenyl]-5-methyl-1,2,4-oxadiazole Chemical compound C1CN(S(=O)(=O)CCCC)CCN1C1=CC=C(C=2N=C(C)ON=2)C=C1 LXGJRZCNBSCWHV-UHFFFAOYSA-N 0.000 description 1
- UWXJEEFTENFOBR-UHFFFAOYSA-N 3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1-piperazin-1-ylpropan-1-one Chemical compound O1C(C)=NC(C=2C=CC(CCC(=O)N3CCNCC3)=CC=2)=N1 UWXJEEFTENFOBR-UHFFFAOYSA-N 0.000 description 1
- OAJJAFVZMPMLGR-UHFFFAOYSA-N 3-[4-[4-(3-chloro-4-methylphenyl)sulfonylpiperazin-1-yl]phenyl]-5-methyl-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)N2CCN(CC2)S(=O)(=O)C=2C=C(Cl)C(C)=CC=2)=N1 OAJJAFVZMPMLGR-UHFFFAOYSA-N 0.000 description 1
- MZXKOXTVAYRURZ-UHFFFAOYSA-N 3-[4-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazin-1-yl]phenyl]-5-methyl-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)N2CCN(CC2)S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)=N1 MZXKOXTVAYRURZ-UHFFFAOYSA-N 0.000 description 1
- NXTXDYDRDZXNIA-UHFFFAOYSA-N 3-[4-[[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]methyl]phenyl]-5-methyl-1,2,4-oxadiazole Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(CC=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 NXTXDYDRDZXNIA-UHFFFAOYSA-N 0.000 description 1
- NCMOPRMLOBMTBT-UHFFFAOYSA-N 3-[4-[[4-[(3,5-dimethoxyphenyl)methyl]piperazin-1-yl]methyl]phenyl]-5-methyl-1,2,4-oxadiazole Chemical compound COC1=CC(OC)=CC(CN2CCN(CC=3C=CC(=CC=3)C=3N=C(C)ON=3)CC2)=C1 NCMOPRMLOBMTBT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GNYVVCRRZRVBDD-UHFFFAOYSA-N 3-chloro-4-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1Cl GNYVVCRRZRVBDD-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KFPMLWUKHQMEBU-UHFFFAOYSA-N 3-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC(S(Cl)(=O)=O)=C1 KFPMLWUKHQMEBU-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BKYPFWBBHJMODH-UHFFFAOYSA-N 4-(4-chlorophenyl)sulfonyl-n-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]piperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(NC(=O)N3CCN(CC3)S(=O)(=O)C=3C=CC(Cl)=CC=3)=CC=2)=N1 BKYPFWBBHJMODH-UHFFFAOYSA-N 0.000 description 1
- SMBDBBBBXFXBSK-UHFFFAOYSA-N 4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl chloride Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(Cl)=O)=N1 SMBDBBBBXFXBSK-UHFFFAOYSA-N 0.000 description 1
- VAPPPANHCHPMGO-UHFFFAOYSA-N 4-(6-chloronaphthalen-2-yl)sulfonyl-n-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]piperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(NC(=O)N3CCN(CC3)S(=O)(=O)C=3C=C4C=CC(Cl)=CC4=CC=3)=CC=2)=N1 VAPPPANHCHPMGO-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- ZXKKOFJYPRJFIE-UHFFFAOYSA-N 4-(trifluoromethoxy)benzoyl chloride Chemical compound FC(F)(F)OC1=CC=C(C(Cl)=O)C=C1 ZXKKOFJYPRJFIE-UHFFFAOYSA-N 0.000 description 1
- UKCPJXYXPORZQT-UHFFFAOYSA-N 4-[(4-phenylphenyl)sulfonyl-piperazin-1-ylmethyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(S(=O)(=O)C=1C=CC(=CC=1)C=1C=CC=CC=1)N1CCNCC1 UKCPJXYXPORZQT-UHFFFAOYSA-N 0.000 description 1
- BWPXASBMFRJJSC-UHFFFAOYSA-N 4-[(6-chloronaphthalen-2-yl)sulfonyl-piperazin-1-ylmethyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(S(=O)(=O)C=1C=C2C=CC(Cl)=CC2=CC=1)N1CCNCC1 BWPXASBMFRJJSC-UHFFFAOYSA-N 0.000 description 1
- RSGJOFCDZUANDR-UHFFFAOYSA-N 4-[2-oxo-2-[4-(4-propylphenyl)sulfonylpiperazin-1-yl]ethyl]benzenecarboximidamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)CC=2C=CC(=CC=2)C(N)=N)CC1 RSGJOFCDZUANDR-UHFFFAOYSA-N 0.000 description 1
- CXLTTZVWIIKGNT-UHFFFAOYSA-N 4-[2-phenylethenylsulfonyl(piperazin-1-yl)methyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(S(=O)(=O)C=CC=1C=CC=CC=1)N1CCNCC1 CXLTTZVWIIKGNT-UHFFFAOYSA-N 0.000 description 1
- ZAIHLGGJTAYQSK-UHFFFAOYSA-N 4-[3-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazin-1-yl]-3-oxopropyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1CCC(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1 ZAIHLGGJTAYQSK-UHFFFAOYSA-N 0.000 description 1
- WHOUDGKKXISPOY-UHFFFAOYSA-N 4-[4-(3-aminobenzoyl)piperazine-1-carbonyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(=O)N1CCN(C(=O)C=2C=C(N)C=CC=2)CC1 WHOUDGKKXISPOY-UHFFFAOYSA-N 0.000 description 1
- TXBDOWJTBJPVKM-UHFFFAOYSA-N 4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]-n-(4-nitrophenyl)piperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)=N1 TXBDOWJTBJPVKM-UHFFFAOYSA-N 0.000 description 1
- XGROWXCLDADPHD-UHFFFAOYSA-N 4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]-n-naphthalen-1-ylpiperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)NC=2C3=CC=CC=C3C=CC=2)=N1 XGROWXCLDADPHD-UHFFFAOYSA-N 0.000 description 1
- MBPLGDZACSYTMO-UHFFFAOYSA-N 4-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazine-1-carbonyl]-3-methylbenzenecarboximidamide Chemical compound CC1=CC(C(N)=N)=CC=C1C(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1 MBPLGDZACSYTMO-UHFFFAOYSA-N 0.000 description 1
- GFTPIDWHZJGMLG-UHFFFAOYSA-N 4-[naphthalen-2-ylsulfonyl(piperazin-1-yl)methyl]benzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1C(S(=O)(=O)C=1C=C2C=CC=CC2=CC=1)N1CCNCC1 GFTPIDWHZJGMLG-UHFFFAOYSA-N 0.000 description 1
- ALOQYFFSHSEVJH-UHFFFAOYSA-N 4-acetamido-3-chlorobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1Cl ALOQYFFSHSEVJH-UHFFFAOYSA-N 0.000 description 1
- GRDXCFKBQWDAJH-UHFFFAOYSA-N 4-acetamidobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1 GRDXCFKBQWDAJH-UHFFFAOYSA-N 0.000 description 1
- UOIVESXBURLTPX-UHFFFAOYSA-N 4-bromo-2-ethylbenzenesulfonyl chloride Chemical compound CCC1=CC(Br)=CC=C1S(Cl)(=O)=O UOIVESXBURLTPX-UHFFFAOYSA-N 0.000 description 1
- OVFZELSNOHIDEF-UHFFFAOYSA-N 4-butylbenzenesulfonyl chloride Chemical compound CCCCC1=CC=C(S(Cl)(=O)=O)C=C1 OVFZELSNOHIDEF-UHFFFAOYSA-N 0.000 description 1
- JBYZPUBAISWVDI-UHFFFAOYSA-N 4-chloro-2,5-dimethylbenzenesulfonyl chloride Chemical compound CC1=CC(S(Cl)(=O)=O)=C(C)C=C1Cl JBYZPUBAISWVDI-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- LACFLXDRFOQEFZ-UHFFFAOYSA-N 4-ethylbenzenesulfonyl chloride Chemical compound CCC1=CC=C(S(Cl)(=O)=O)C=C1 LACFLXDRFOQEFZ-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- OGHAPVZVXLHURO-UHFFFAOYSA-N 4-methoxy-2-nitrobenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C([N+]([O-])=O)=C1 OGHAPVZVXLHURO-UHFFFAOYSA-N 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- PBXXVZQVRUKRKC-UHFFFAOYSA-N 5-(dimethylamino)naphthalene-1-sulfonyl chloride 1-[4-[5-(dimethylamino)naphthalen-1-yl]sulfonylpiperazin-1-yl]-2-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]ethanone Chemical compound CN(C)c1cccc2c(cccc12)S(Cl)(=O)=O.CN(C)c1cccc2c(cccc12)S(=O)(=O)N1CCN(CC1)C(=O)Cc1ccc(cc1)-c1noc(C)n1 PBXXVZQVRUKRKC-UHFFFAOYSA-N 0.000 description 1
- BWVNHXIGDZASCP-UHFFFAOYSA-N 5-[1-methyl-5-(trifluoromethyl)pyrazol-3-yl]thiophene-2-sulfonyl chloride Chemical compound C1=C(C(F)(F)F)N(C)N=C1C1=CC=C(S(Cl)(=O)=O)S1 BWVNHXIGDZASCP-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- HWGVUNSKAPCFNF-UHFFFAOYSA-N 5-chloro-1,3-dimethylpyrazole-4-sulfonyl chloride Chemical compound CC1=NN(C)C(Cl)=C1S(Cl)(=O)=O HWGVUNSKAPCFNF-UHFFFAOYSA-N 0.000 description 1
- MICVPVPQQNFKGU-UHFFFAOYSA-N 5-chloronaphthalene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2C(Cl)=CC=CC2=C1 MICVPVPQQNFKGU-UHFFFAOYSA-N 0.000 description 1
- NPNTVEOHEIJADR-UHFFFAOYSA-N 5-methyl-3-(4-piperazin-1-ylphenyl)-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)N2CCNCC2)=N1 NPNTVEOHEIJADR-UHFFFAOYSA-N 0.000 description 1
- XIRGQQZVRFVVEW-UHFFFAOYSA-N 5-methyl-3-[4-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)phenyl]-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)N2CCN(CC2)S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=N1 XIRGQQZVRFVVEW-UHFFFAOYSA-N 0.000 description 1
- VJRDYURNXPQISC-UHFFFAOYSA-N 5-methyl-3-[4-(piperazin-1-ylmethyl)phenyl]-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(CN3CCNCC3)=CC=2)=N1 VJRDYURNXPQISC-UHFFFAOYSA-N 0.000 description 1
- PZVYUAHCDZJODN-UHFFFAOYSA-N 5-methyl-3-[4-[4-(2,4,6-trimethylphenyl)sulfonylpiperazin-1-yl]phenyl]-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)N2CCN(CC2)S(=O)(=O)C=2C(=CC(C)=CC=2C)C)=N1 PZVYUAHCDZJODN-UHFFFAOYSA-N 0.000 description 1
- FMLLHWFPVZDTCC-UHFFFAOYSA-N 5-methyl-3-[4-[4-(4-propylphenyl)sulfonylpiperazin-1-yl]phenyl]-1,2,4-oxadiazole Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 FMLLHWFPVZDTCC-UHFFFAOYSA-N 0.000 description 1
- SLNZRZNAEQHSAA-UHFFFAOYSA-N 5-methyl-3-[4-[[4-(4-propylphenyl)sulfonylpiperazin-1-yl]methyl]phenyl]-1,2,4-oxadiazole Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(CC=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 SLNZRZNAEQHSAA-UHFFFAOYSA-N 0.000 description 1
- YAOVXDACVMPREX-UHFFFAOYSA-N 5-methyl-3-[4-[[4-(naphthalen-2-ylmethyl)piperazin-1-yl]methyl]phenyl]-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=CC(CN3CCN(CC=4C=C5C=CC=CC5=CC=4)CC3)=CC=2)=N1 YAOVXDACVMPREX-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LOYHMYJZBTXBGW-UHFFFAOYSA-N C(C)(=O)O.BrC=1C=C(C=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.BrC=1C=C(C=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 LOYHMYJZBTXBGW-UHFFFAOYSA-N 0.000 description 1
- IKVAYEZKPZXRSQ-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)NC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)Cl Chemical compound C(C)(=O)O.C(C)(=O)NC1=C(C=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)Cl IKVAYEZKPZXRSQ-UHFFFAOYSA-N 0.000 description 1
- ZPLZFRFZGYFWPN-UHFFFAOYSA-N C(C)(=O)O.C(C)(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.C(C)(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 ZPLZFRFZGYFWPN-UHFFFAOYSA-N 0.000 description 1
- WMXKSDKSZLWFIT-UHFFFAOYSA-N C(C)(=O)O.C(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.C(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 WMXKSDKSZLWFIT-UHFFFAOYSA-N 0.000 description 1
- HVCYUNHPBKMOND-UHFFFAOYSA-N C(C)(=O)O.C(CC)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.C(CC)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 HVCYUNHPBKMOND-UHFFFAOYSA-N 0.000 description 1
- OUJRUCKYSONBAV-UHFFFAOYSA-N C(C)(=O)O.C(CCCCCCCCC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.C(CCCCCCCCC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 OUJRUCKYSONBAV-UHFFFAOYSA-N 0.000 description 1
- MASRCPUDQHDKEI-UHFFFAOYSA-N C(C)(=O)O.C(N)(=N)C1=CC=C(C=C1)N1CCN(CC1)S(=O)(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound C(C)(=O)O.C(N)(=N)C1=CC=C(C=C1)N1CCN(CC1)S(=O)(=O)C1=CC2=CC=CC=C2C=C1 MASRCPUDQHDKEI-UHFFFAOYSA-N 0.000 description 1
- CXIXWMGGRGEVJP-UHFFFAOYSA-N C(C)(=O)O.C(N)(=N)C1=CC=C(CN2CCN(CC2)CC2=CC(=CC(=C2)OC)OC)C=C1 Chemical compound C(C)(=O)O.C(N)(=N)C1=CC=C(CN2CCN(CC2)CC2=CC(=CC(=C2)OC)OC)C=C1 CXIXWMGGRGEVJP-UHFFFAOYSA-N 0.000 description 1
- HYIZPUKZLHYUGA-UHFFFAOYSA-N C(C)(=O)O.C1(=CC(=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C Chemical compound C(C)(=O)O.C1(=CC(=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C HYIZPUKZLHYUGA-UHFFFAOYSA-N 0.000 description 1
- NIXARMLKWNLUGS-UHFFFAOYSA-N C(C)(=O)O.C1(=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C Chemical compound C(C)(=O)O.C1(=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C NIXARMLKWNLUGS-UHFFFAOYSA-N 0.000 description 1
- XWKFJNWYADOUCL-UHFFFAOYSA-N C(C)(=O)O.C1(=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1)C1=CC=CC=C1 Chemical compound C(C)(=O)O.C1(=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1)C1=CC=CC=C1 XWKFJNWYADOUCL-UHFFFAOYSA-N 0.000 description 1
- NNUIKTKILISLEC-UHFFFAOYSA-N C(C)(=O)O.C1(=CC=CC=C1)C1=CC=C(C(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C=C1 Chemical compound C(C)(=O)O.C1(=CC=CC=C1)C1=CC=C(C(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C=C1 NNUIKTKILISLEC-UHFFFAOYSA-N 0.000 description 1
- JZMUHBAVSWHUAP-UHFFFAOYSA-N C(C)(=O)O.C1(=CC=CC=C1)C=CS(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.C1(=CC=CC=C1)C=CS(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 JZMUHBAVSWHUAP-UHFFFAOYSA-N 0.000 description 1
- LHMLHITZUGKTPP-UHFFFAOYSA-N C(C)(=O)O.C1(=CC=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.C1(=CC=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 LHMLHITZUGKTPP-UHFFFAOYSA-N 0.000 description 1
- KVQOIUQVPSMWPX-UHFFFAOYSA-N C(C)(=O)O.C1=C(C=CC2=CC=CC=C12)CN1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.C1=C(C=CC2=CC=CC=C12)CN1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 KVQOIUQVPSMWPX-UHFFFAOYSA-N 0.000 description 1
- OETGWRRCCLJSDG-UHFFFAOYSA-N C(C)(=O)O.C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 Chemical compound C(C)(=O)O.C1=C(C=CC2=CC=CC=C12)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 OETGWRRCCLJSDG-UHFFFAOYSA-N 0.000 description 1
- JMYRJYRBNLMPGX-UHFFFAOYSA-N C(C)(=O)O.C1=C(C=CC=2OC3=C(C21)C=CC=C3)S(=O)(=O)N3CCN(CC3)C(=O)C3=CC=C(C(=N)N)C=C3 Chemical compound C(C)(=O)O.C1=C(C=CC=2OC3=C(C21)C=CC=C3)S(=O)(=O)N3CCN(CC3)C(=O)C3=CC=C(C(=N)N)C=C3 JMYRJYRBNLMPGX-UHFFFAOYSA-N 0.000 description 1
- VEDIWVMUSUSBNU-UHFFFAOYSA-N C(C)(=O)O.CN(C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C Chemical compound C(C)(=O)O.CN(C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C VEDIWVMUSUSBNU-UHFFFAOYSA-N 0.000 description 1
- ZNMRIHOSYXORMZ-UHFFFAOYSA-N C(C)(=O)O.COC(=O)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.COC(=O)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 ZNMRIHOSYXORMZ-UHFFFAOYSA-N 0.000 description 1
- NBUKRMPVNQMBKB-UHFFFAOYSA-N C(C)(=O)O.COC1=C(C=C(C=C1)C)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.COC1=C(C=C(C=C1)C)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 NBUKRMPVNQMBKB-UHFFFAOYSA-N 0.000 description 1
- KVMNRVNTSVYIHE-UHFFFAOYSA-N C(C)(=O)O.COC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.COC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 KVMNRVNTSVYIHE-UHFFFAOYSA-N 0.000 description 1
- PILGXBMOAHYQLD-UHFFFAOYSA-N C(C)(=O)O.CS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.CS(=O)(=O)C1=C(C=CC=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 PILGXBMOAHYQLD-UHFFFAOYSA-N 0.000 description 1
- MENGGCOOSRZKQT-UHFFFAOYSA-N C(C)(=O)O.CS(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.CS(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 MENGGCOOSRZKQT-UHFFFAOYSA-N 0.000 description 1
- AOMRNZJHKWMCQQ-UHFFFAOYSA-N C(C)(=O)O.ClC1=C(C(=CC(=C1)Cl)Cl)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 Chemical compound C(C)(=O)O.ClC1=C(C(=CC(=C1)Cl)Cl)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 AOMRNZJHKWMCQQ-UHFFFAOYSA-N 0.000 description 1
- NSHPIPNPVAYEKL-UHFFFAOYSA-N C(C)(=O)O.ClC1=C(C(=CC(=C1)Cl)OC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.ClC1=C(C(=CC(=C1)Cl)OC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 NSHPIPNPVAYEKL-UHFFFAOYSA-N 0.000 description 1
- LOGMNWYABGSYCG-UHFFFAOYSA-N C(C)(=O)O.ClC1=C(C=CC=C1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.ClC1=C(C=CC=C1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 LOGMNWYABGSYCG-UHFFFAOYSA-N 0.000 description 1
- BDSUYCRRIWETKN-UHFFFAOYSA-N C(C)(=O)O.ClC1=CC(=C(C=C1C)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C Chemical compound C(C)(=O)O.ClC1=CC(=C(C=C1C)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)C BDSUYCRRIWETKN-UHFFFAOYSA-N 0.000 description 1
- ZAYWKYKCNWYDPS-UHFFFAOYSA-N C(C)(=O)O.ClC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 Chemical compound C(C)(=O)O.ClC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 ZAYWKYKCNWYDPS-UHFFFAOYSA-N 0.000 description 1
- WHGMXADIHAYEMH-UHFFFAOYSA-N C(C)(=O)O.ClC=1C=C(C(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C=CC1Cl Chemical compound C(C)(=O)O.ClC=1C=C(C(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C=CC1Cl WHGMXADIHAYEMH-UHFFFAOYSA-N 0.000 description 1
- MNKQVKAZCZYMMT-UHFFFAOYSA-N C(C)(=O)O.ClC=1C=C(C=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.ClC=1C=C(C=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 MNKQVKAZCZYMMT-UHFFFAOYSA-N 0.000 description 1
- DTQXFGAPINFFQH-UHFFFAOYSA-N C(C)(=O)O.ClC=1C=C(C=CC1C)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.ClC=1C=C(C=CC1C)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 DTQXFGAPINFFQH-UHFFFAOYSA-N 0.000 description 1
- ZTYHTZVVNHMXRF-UHFFFAOYSA-N C(C)(=O)O.ClC=1C=C(C=CC1C)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 Chemical compound C(C)(=O)O.ClC=1C=C(C=CC1C)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 ZTYHTZVVNHMXRF-UHFFFAOYSA-N 0.000 description 1
- AXPSHHMBKJUKIQ-UHFFFAOYSA-N C(C)(=O)O.ClC=1C=C(C=CC1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.ClC=1C=C(C=CC1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 AXPSHHMBKJUKIQ-UHFFFAOYSA-N 0.000 description 1
- RXNNGPMKPJTLLG-UHFFFAOYSA-N C(C)(=O)O.ClC=1C=C2C=CC(=CC2=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.ClC=1C=C2C=CC(=CC2=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 RXNNGPMKPJTLLG-UHFFFAOYSA-N 0.000 description 1
- AGTOIZRESORIDV-UHFFFAOYSA-N C(C)(=O)O.FC(C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)(F)F Chemical compound C(C)(=O)O.FC(C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1)(F)F AGTOIZRESORIDV-UHFFFAOYSA-N 0.000 description 1
- UGJSMFCPLDDBMY-UHFFFAOYSA-N C(C)(=O)O.FC(C=1C=C(C=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1)(F)F Chemical compound C(C)(=O)O.FC(C=1C=C(C=CC1)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1)(F)F UGJSMFCPLDDBMY-UHFFFAOYSA-N 0.000 description 1
- XOHDGLZAIKDGOX-UHFFFAOYSA-N C(C)(=O)O.FC(OC1=CC=C(C(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C=C1)(F)F Chemical compound C(C)(=O)O.FC(OC1=CC=C(C(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C=C1)(F)F XOHDGLZAIKDGOX-UHFFFAOYSA-N 0.000 description 1
- DQPOUQJBZVUYJS-UHFFFAOYSA-N C(C)(=O)O.FC=1C=C(C=CC1OC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.FC=1C=C(C=CC1OC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 DQPOUQJBZVUYJS-UHFFFAOYSA-N 0.000 description 1
- XTYYTKNHDATGKT-UHFFFAOYSA-N C(C)(=O)O.NC1=C(C=CC(=C1)OC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.NC1=C(C=CC(=C1)OC)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 XTYYTKNHDATGKT-UHFFFAOYSA-N 0.000 description 1
- QLHJMNGLTYQDPV-UHFFFAOYSA-N C(C)(=O)O.NC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.NC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 QLHJMNGLTYQDPV-UHFFFAOYSA-N 0.000 description 1
- LQUABFIAOKHCBE-UHFFFAOYSA-N C(C)(=O)O.NC=1C=C(C=CC1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.NC=1C=C(C=CC1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 LQUABFIAOKHCBE-UHFFFAOYSA-N 0.000 description 1
- CVYLGBRQAWNNJZ-UHFFFAOYSA-N C(C)(=O)O.NC=1C=C(C=CC1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 Chemical compound C(C)(=O)O.NC=1C=C(C=CC1Cl)S(=O)(=O)N1CCN(CC1)C(=O)C=1C=C(C(=N)N)C=CC1 CVYLGBRQAWNNJZ-UHFFFAOYSA-N 0.000 description 1
- ASGSXGPVUBOMPO-UHFFFAOYSA-N C(C)(=O)O.NC=1C=C(CS(=O)(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C(=CC1)C Chemical compound C(C)(=O)O.NC=1C=C(CS(=O)(=O)N2CCN(CC2)C(=O)C2=CC=C(C(=N)N)C=C2)C(=CC1)C ASGSXGPVUBOMPO-UHFFFAOYSA-N 0.000 description 1
- VNBRZBUVVVSBTL-UHFFFAOYSA-N C(C)(=O)O.O(C1=CC=CC=C1)CC(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 Chemical compound C(C)(=O)O.O(C1=CC=CC=C1)CC(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1 VNBRZBUVVVSBTL-UHFFFAOYSA-N 0.000 description 1
- RDTDCJGWDKPKOM-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C RDTDCJGWDKPKOM-UHFFFAOYSA-N 0.000 description 1
- XHVYPDCCLCDOOB-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C(C)C Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C(C)C XHVYPDCCLCDOOB-UHFFFAOYSA-N 0.000 description 1
- PSRAJMRRTJAZEK-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl PSRAJMRRTJAZEK-UHFFFAOYSA-N 0.000 description 1
- NGYTVPUNXIDXTH-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC(=C(C=C1)OC)OC Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC(=C(C=C1)OC)OC NGYTVPUNXIDXTH-UHFFFAOYSA-N 0.000 description 1
- LEGWCEOVHZYOPS-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=CC2=CC=CC=C12 Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=CC2=CC=CC=C12 LEGWCEOVHZYOPS-UHFFFAOYSA-N 0.000 description 1
- YIYKZZAIXOMVJM-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=CC=C1 Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=CC=C1 YIYKZZAIXOMVJM-UHFFFAOYSA-N 0.000 description 1
- RQLKEAHTORTVGI-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C=CC1=CC=CC=C1 Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C=CC1=CC=CC=C1 RQLKEAHTORTVGI-UHFFFAOYSA-N 0.000 description 1
- RNBZSQUZGNWTQS-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)CC1=CC=CC=C1 Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)CC1=CC=CC=C1 RNBZSQUZGNWTQS-UHFFFAOYSA-N 0.000 description 1
- ADWVASLPGHSXJF-UHFFFAOYSA-N C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)CCCCCCCCCC Chemical compound C(C)(=O)O.O=C(CC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)CCCCCCCCCC ADWVASLPGHSXJF-UHFFFAOYSA-N 0.000 description 1
- LYICCZRDXUTZPC-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC(=C(C=C1)C)Cl Chemical compound C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC(=C(C=C1)C)Cl LYICCZRDXUTZPC-UHFFFAOYSA-N 0.000 description 1
- CNBMJFYJBGFADH-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC2=CC=CC=C2C=C1 CNBMJFYJBGFADH-UHFFFAOYSA-N 0.000 description 1
- AUPSOCAGQZINKN-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1 Chemical compound C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1 AUPSOCAGQZINKN-UHFFFAOYSA-N 0.000 description 1
- YBMAOOGTWHOINC-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)CCC Chemical compound C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)CCC YBMAOOGTWHOINC-UHFFFAOYSA-N 0.000 description 1
- OHVLEXDHZPHVSI-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)Cl Chemical compound C(C)(=O)O.O=C(CCC1=CC=C(C(=N)N)C=C1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)Cl OHVLEXDHZPHVSI-UHFFFAOYSA-N 0.000 description 1
- TZHOHBFNHHQJBP-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=C(C=C(C=C1C)C)C Chemical compound C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=C(C=C(C=C1C)C)C TZHOHBFNHHQJBP-UHFFFAOYSA-N 0.000 description 1
- HZJCSBJONUGUGF-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=CC(=C(C=C1)C)Cl Chemical compound C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=CC(=C(C=C1)C)Cl HZJCSBJONUGUGF-UHFFFAOYSA-N 0.000 description 1
- MNBPKURIKQACDO-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=CC2=CC=CC=C2C=C1 Chemical compound C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=CC2=CC=CC=C2C=C1 MNBPKURIKQACDO-UHFFFAOYSA-N 0.000 description 1
- NPPCPWDYIWKDQY-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1 Chemical compound C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1=CC=CC=C1 NPPCPWDYIWKDQY-UHFFFAOYSA-N 0.000 description 1
- XOYXTDQYNLLENX-UHFFFAOYSA-N C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)CCCC Chemical compound C(C)(=O)O.O=C(CCC=1C=C(C(=N)N)C=CC1)N1CCN(CC1)S(=O)(=O)CCCC XOYXTDQYNLLENX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- ARGABROETYHEBZ-UHFFFAOYSA-N ClC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1.C(C)(=O)O Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C(=N)N)C=C1.C(C)(=O)O ARGABROETYHEBZ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 101100134925 Gallus gallus COR6 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- SFWMNPRILVLLNF-UHFFFAOYSA-N N1=CC=CC2=CC=CC(=C12)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=NOC(=N1)C Chemical compound N1=CC=CC2=CC=CC(=C12)S(=O)(=O)N1CCN(CC1)C(=O)C1=CC=C(C=C1)C1=NOC(=N1)C SFWMNPRILVLLNF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- VHQJTTAVWWDHAD-UHFFFAOYSA-N [4-(1,3-benzodioxole-5-carbonyl)piperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2C=C3OCOC3=CC=2)=N1 VHQJTTAVWWDHAD-UHFFFAOYSA-N 0.000 description 1
- JKBFFERUQAUXNB-UHFFFAOYSA-N [4-(2,3-dichlorophenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C(=C(Cl)C=CC=2)Cl)=N1 JKBFFERUQAUXNB-UHFFFAOYSA-N 0.000 description 1
- PGKLSNFBPJPTMB-UHFFFAOYSA-N [4-(2,5-dichlorophenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C(=CC=C(Cl)C=2)Cl)=N1 PGKLSNFBPJPTMB-UHFFFAOYSA-N 0.000 description 1
- OYKWAIATSNZTJE-UHFFFAOYSA-N [4-(2-methoxy-5-methylphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 OYKWAIATSNZTJE-UHFFFAOYSA-N 0.000 description 1
- QFMUUJFFFWEIJD-UHFFFAOYSA-N [4-(3,4-dichlorobenzoyl)piperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2C=C(Cl)C(Cl)=CC=2)=N1 QFMUUJFFFWEIJD-UHFFFAOYSA-N 0.000 description 1
- KBZTYOHTHDNCSV-UHFFFAOYSA-N [4-(3,4-difluorophenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=C(F)C(F)=CC=2)=N1 KBZTYOHTHDNCSV-UHFFFAOYSA-N 0.000 description 1
- MCNONBNDNHLDEY-UHFFFAOYSA-N [4-(3,4-dimethoxyphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 MCNONBNDNHLDEY-UHFFFAOYSA-N 0.000 description 1
- YELKRDFCPLHMQI-UHFFFAOYSA-N [4-(3-chloro-4-methylphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=C(Cl)C(C)=CC=2)=N1 YELKRDFCPLHMQI-UHFFFAOYSA-N 0.000 description 1
- XTJTZVKREUJUDI-UHFFFAOYSA-N [4-(4-bromo-2-ethylphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound CCC1=CC(Br)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 XTJTZVKREUJUDI-UHFFFAOYSA-N 0.000 description 1
- WBQSBRNWBIQIAQ-UHFFFAOYSA-N [4-(4-butylphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound C1=CC(CCCC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 WBQSBRNWBIQIAQ-UHFFFAOYSA-N 0.000 description 1
- JKRGDGNBDSMWHY-UHFFFAOYSA-N [4-(4-chloro-2,5-dimethylphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C(=CC(Cl)=C(C)C=2)C)=N1 JKRGDGNBDSMWHY-UHFFFAOYSA-N 0.000 description 1
- GHBIVKJXUIQVBN-UHFFFAOYSA-N [4-(4-chlorophenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC(Cl)=CC=2)=N1 GHBIVKJXUIQVBN-UHFFFAOYSA-N 0.000 description 1
- HATHMWNDSDOWJJ-UHFFFAOYSA-N [4-(4-ethylphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 HATHMWNDSDOWJJ-UHFFFAOYSA-N 0.000 description 1
- REIFGYORSIPRLU-UHFFFAOYSA-N [4-(4-methoxy-2-nitrophenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound [O-][N+](=O)C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 REIFGYORSIPRLU-UHFFFAOYSA-N 0.000 description 1
- QBSLINCUEUPGMO-UHFFFAOYSA-N [4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 QBSLINCUEUPGMO-UHFFFAOYSA-N 0.000 description 1
- BKFSMJDURCVBJG-UHFFFAOYSA-N [4-(5-chloro-1,3-dimethylpyrazol-4-yl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C2=C(N(C)N=C2C)Cl)=N1 BKFSMJDURCVBJG-UHFFFAOYSA-N 0.000 description 1
- NIYRWTYHYGEGFI-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-(4-methylsulfonylpiperazin-1-yl)methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(C)(=O)=O)=N1 NIYRWTYHYGEGFI-UHFFFAOYSA-N 0.000 description 1
- PHTRJLHWRPLIIF-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-(4-naphthalen-1-ylsulfonylpiperazin-1-yl)methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=N1 PHTRJLHWRPLIIF-UHFFFAOYSA-N 0.000 description 1
- FEONFIDAWBBDCR-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=N1 FEONFIDAWBBDCR-UHFFFAOYSA-N 0.000 description 1
- ZDKIMNCHMGDTQF-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-(4-propan-2-ylsulfonylpiperazin-1-yl)methanone Chemical compound C1CN(S(=O)(=O)C(C)C)CCN1C(=O)C1=CC=C(C=2N=C(C)ON=2)C=C1 ZDKIMNCHMGDTQF-UHFFFAOYSA-N 0.000 description 1
- DHJVUXNUVYCHSL-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-(4-thiophen-2-ylsulfonylpiperazin-1-yl)methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2SC=CC=2)=N1 DHJVUXNUVYCHSL-UHFFFAOYSA-N 0.000 description 1
- CKCWUCLMXJLTHJ-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-(3-nitrobenzoyl)piperazin-1-yl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=N1 CKCWUCLMXJLTHJ-UHFFFAOYSA-N 0.000 description 1
- IIIGILACKIYQCL-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC(C)=CC=2)=N1 IIIGILACKIYQCL-UHFFFAOYSA-N 0.000 description 1
- OVTIWMXHZVONMZ-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-(4-nitrophenyl)sulfonylpiperazin-1-yl]methanone;4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1.O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=N1 OVTIWMXHZVONMZ-UHFFFAOYSA-N 0.000 description 1
- GFJNXIZHMVBQJM-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-(4-phenylphenyl)sulfonylpiperazin-1-yl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 GFJNXIZHMVBQJM-UHFFFAOYSA-N 0.000 description 1
- CCMNIRNOSXYSJK-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-(4-propylphenyl)sulfonylpiperazin-1-yl]methanone Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 CCMNIRNOSXYSJK-UHFFFAOYSA-N 0.000 description 1
- CYYKSELDONEETL-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-(pyridine-3-carbonyl)piperazin-1-yl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2C=NC=CC=2)=N1 CYYKSELDONEETL-UHFFFAOYSA-N 0.000 description 1
- DZTCQPVLGQWNPH-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-[(2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-yl)sulfonyl]piperazin-1-yl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C(=C3CCC(C)(C)OC3=C(C)C=2C)C)=N1 DZTCQPVLGQWNPH-UHFFFAOYSA-N 0.000 description 1
- HXJDAPRGZRUFRI-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-[4-[4-(trifluoromethoxy)benzoyl]piperazin-1-yl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2C=CC(OC(F)(F)F)=CC=2)=N1 HXJDAPRGZRUFRI-UHFFFAOYSA-N 0.000 description 1
- KHQGLPBVNJZDRO-UHFFFAOYSA-N [4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-piperazin-1-ylmethanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCNCC2)=N1 KHQGLPBVNJZDRO-UHFFFAOYSA-N 0.000 description 1
- CWOLYRCVRHVJEF-UHFFFAOYSA-N [4-(6-chloronaphthalen-2-yl)sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)=N1 CWOLYRCVRHVJEF-UHFFFAOYSA-N 0.000 description 1
- FXIUYYJFQKWNBV-UHFFFAOYSA-N [4-(benzenesulfonyl)piperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)=N1 FXIUYYJFQKWNBV-UHFFFAOYSA-N 0.000 description 1
- NFAMCOWYHVQFAU-UHFFFAOYSA-N [4-[(2-methyl-5-nitrophenyl)methylsulfonyl]piperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)CC=2C(=CC=C(C=2)[N+]([O-])=O)C)=N1 NFAMCOWYHVQFAU-UHFFFAOYSA-N 0.000 description 1
- IWYBLDWFULNRAO-UHFFFAOYSA-N [4-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfonyl]piperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C2=C(ON=C2C)C)=N1 IWYBLDWFULNRAO-UHFFFAOYSA-N 0.000 description 1
- GKXDWJGMSOPCSV-UHFFFAOYSA-N [4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]-(4-phenylphenyl)methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 GKXDWJGMSOPCSV-UHFFFAOYSA-N 0.000 description 1
- BTVKPWQEMSVRKZ-UHFFFAOYSA-N [4-[5-(dimethylamino)naphthalen-1-yl]sulfonylpiperazin-1-yl]-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methanone Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)N(CC1)CCN1C(=O)C(C=C1)=CC=C1C1=NOC(C)=N1 BTVKPWQEMSVRKZ-UHFFFAOYSA-N 0.000 description 1
- BNFDHOKRSXZOIX-UHFFFAOYSA-N [4-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]piperazin-1-yl]-naphthalen-2-ylmethanone Chemical compound O1C(C)=NC(C=2C=CC(CN3CCN(CC3)C(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 BNFDHOKRSXZOIX-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- PJHUABJTDFXYRQ-UHFFFAOYSA-N benzoyl azide Chemical compound [N-]=[N+]=NC(=O)C1=CC=CC=C1 PJHUABJTDFXYRQ-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
- WEDIIKBPDQQQJU-UHFFFAOYSA-N butane-1-sulfonyl chloride Chemical compound CCCCS(Cl)(=O)=O WEDIIKBPDQQQJU-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- OBYFJZMEJNHFHC-UHFFFAOYSA-N cyclopentyl-[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]methanone Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)C2CCCC2)=N1 OBYFJZMEJNHFHC-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- NUEYULKJUMENGF-UHFFFAOYSA-N ethyl 3-[[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazine-1-carbonyl]amino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NC(=O)N2CCN(CC2)C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)=C1 NUEYULKJUMENGF-UHFFFAOYSA-N 0.000 description 1
- UPXGGIRFDZENRD-UHFFFAOYSA-N ethyl 3-isocyanatobenzoate Chemical compound CCOC(=O)C1=CC=CC(N=C=O)=C1 UPXGGIRFDZENRD-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- FEAACKGLTFWWSJ-UHFFFAOYSA-N n-(4-carbamimidoylphenyl)-4-(2-phenylethenylsulfonyl)piperazine-1-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)N1CCN(S(=O)(=O)C=CC=2C=CC=CC=2)CC1 FEAACKGLTFWWSJ-UHFFFAOYSA-N 0.000 description 1
- FUYDRTHBHUKTOE-UHFFFAOYSA-N n-(4-carbamimidoylphenyl)-4-(4-chlorophenyl)sulfonylpiperazine-1-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)N1CCN(S(=O)(=O)C=2C=CC(Cl)=CC=2)CC1 FUYDRTHBHUKTOE-UHFFFAOYSA-N 0.000 description 1
- OGTCOBPMCVPAHG-UHFFFAOYSA-N n-(4-carbamimidoylphenyl)-4-(4-phenylphenyl)sulfonylpiperazine-1-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)N1CCN(S(=O)(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 OGTCOBPMCVPAHG-UHFFFAOYSA-N 0.000 description 1
- DECNNJZZCQVDDY-UHFFFAOYSA-N n-(4-carbamimidoylphenyl)-4-(4-propylphenyl)sulfonylpiperazine-1-carboxamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)C(N)=N)CC1 DECNNJZZCQVDDY-UHFFFAOYSA-N 0.000 description 1
- HAHJTWFTDKAYAZ-UHFFFAOYSA-N n-(4-carbamimidoylphenyl)-4-(6-chloronaphthalen-2-yl)sulfonylpiperazine-1-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1 HAHJTWFTDKAYAZ-UHFFFAOYSA-N 0.000 description 1
- SAHOYVSJLLBPNR-UHFFFAOYSA-N n-(4-carbamimidoylphenyl)-4-naphthalen-2-ylsulfonylpiperazine-1-carboxamide Chemical compound C1=CC(C(=N)N)=CC=C1NC(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 SAHOYVSJLLBPNR-UHFFFAOYSA-N 0.000 description 1
- RCFONTIQFPGPOR-UHFFFAOYSA-N n-(4-methoxyphenyl)-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazine-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 RCFONTIQFPGPOR-UHFFFAOYSA-N 0.000 description 1
- NORXYXOCGGVFLK-UHFFFAOYSA-N n-[2-chloro-4-[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]sulfonylphenyl]acetamide Chemical compound C1=C(Cl)C(NC(=O)C)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 NORXYXOCGGVFLK-UHFFFAOYSA-N 0.000 description 1
- MKPGKCKVTRZRAW-UHFFFAOYSA-N n-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-4-(2,4,6-trimethylphenyl)sulfonylpiperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(NC(=O)N3CCN(CC3)S(=O)(=O)C=3C(=CC(C)=CC=3C)C)=CC=2)=N1 MKPGKCKVTRZRAW-UHFFFAOYSA-N 0.000 description 1
- ZOHVQLOAZQKPKL-UHFFFAOYSA-N n-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-4-(2-phenylethenylsulfonyl)piperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(NC(=O)N3CCN(CC3)S(=O)(=O)C=CC=3C=CC=CC=3)=CC=2)=N1 ZOHVQLOAZQKPKL-UHFFFAOYSA-N 0.000 description 1
- AUXJXZXYKLAXSZ-UHFFFAOYSA-N n-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-4-(4-propylphenyl)sulfonylpiperazine-1-carboxamide Chemical compound C1=CC(CCC)=CC=C1S(=O)(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 AUXJXZXYKLAXSZ-UHFFFAOYSA-N 0.000 description 1
- TUOVBVUSWHDGKW-UHFFFAOYSA-N n-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-4-naphthalen-2-ylsulfonylpiperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(NC(=O)N3CCN(CC3)S(=O)(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 TUOVBVUSWHDGKW-UHFFFAOYSA-N 0.000 description 1
- KQRGHLAZECBMIJ-UHFFFAOYSA-N n-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]piperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(NC(=O)N3CCNCC3)=CC=2)=N1 KQRGHLAZECBMIJ-UHFFFAOYSA-N 0.000 description 1
- BSOQKBUFLIEAMO-UHFFFAOYSA-N n-[4-[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]sulfonylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)N1CCN(C(=O)C=2C=CC(=CC=2)C=2N=C(C)ON=2)CC1 BSOQKBUFLIEAMO-UHFFFAOYSA-N 0.000 description 1
- KBIQUUKYTGHPQB-UHFFFAOYSA-N n-[[5-[4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazin-1-yl]sulfonylthiophen-2-yl]methyl]benzamide Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)S(=O)(=O)C=2SC(CNC(=O)C=3C=CC=CC=3)=CC=2)=N1 KBIQUUKYTGHPQB-UHFFFAOYSA-N 0.000 description 1
- WWCMDOJWDCFIIB-UHFFFAOYSA-N n-[amino-[4-[4-(6-chloronaphthalen-2-yl)sulfonylpiperazine-1-carbonyl]phenyl]methylidene]acetamide Chemical compound C1=CC(C(=N)NC(=O)C)=CC=C1C(=O)N1CCN(S(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1 WWCMDOJWDCFIIB-UHFFFAOYSA-N 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- GYSPSKZMWKTTGJ-UHFFFAOYSA-N n-butyl-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazine-1-carboxamide Chemical compound C1CN(C(=O)NCCCC)CCN1C(=O)C1=CC=C(C=2N=C(C)ON=2)C=C1 GYSPSKZMWKTTGJ-UHFFFAOYSA-N 0.000 description 1
- LNVYUTKFKPIPGN-UHFFFAOYSA-N n-cyclohexyl-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazine-1-carboxamide Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)NC2CCCCC2)=N1 LNVYUTKFKPIPGN-UHFFFAOYSA-N 0.000 description 1
- XNLBCXGRQWUJLU-UHFFFAOYSA-N naphthalene-2-carbonyl chloride Chemical compound C1=CC=CC2=CC(C(=O)Cl)=CC=C21 XNLBCXGRQWUJLU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- JUYUYCIJACTHMK-UHFFFAOYSA-N quinoline-8-sulfonyl chloride Chemical compound C1=CN=C2C(S(=O)(=O)Cl)=CC=CC2=C1 JUYUYCIJACTHMK-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- PUGUQINMNYINPK-UHFFFAOYSA-N tert-butyl 4-(2-chloroacetyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)CCl)CC1 PUGUQINMNYINPK-UHFFFAOYSA-N 0.000 description 1
- ZAECAOSXCPXBPI-UHFFFAOYSA-N tert-butyl 4-[(4-cyanophenyl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=C(C#N)C=C1 ZAECAOSXCPXBPI-UHFFFAOYSA-N 0.000 description 1
- UIVQQOGNLTZXHZ-UHFFFAOYSA-N tert-butyl 4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]piperazine-1-carboxylate Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(=O)N2CCN(CC2)C(=O)OC(C)(C)C)=N1 UIVQQOGNLTZXHZ-UHFFFAOYSA-N 0.000 description 1
- KKUJDIZFXGMVNW-UHFFFAOYSA-N tert-butyl 4-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]carbamoyl]piperazine-1-carboxylate Chemical compound O1C(C)=NC(C=2C=CC(NC(=O)N3CCN(CC3)C(=O)OC(C)(C)C)=CC=2)=N1 KKUJDIZFXGMVNW-UHFFFAOYSA-N 0.000 description 1
- XUPZTLJRVSSAHE-UHFFFAOYSA-N tert-butyl 4-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]piperazine-1-carboxylate Chemical compound O1C(C)=NC(C=2C=CC(CN3CCN(CC3)C(=O)OC(C)(C)C)=CC=2)=N1 XUPZTLJRVSSAHE-UHFFFAOYSA-N 0.000 description 1
- VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
Oppfinnelsen vedrører forbindelser med formel I
hvor
R<1>er -C(=NH)-NH2/som også kan være monosubstituert med
-COA, -CO-[C(R6) 2 ] n~Ar, -COOA, -0H eller med en vanlig aminobeskyttelsesgruppe,
R<2>er H, A, OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, NHCOAr,
NHS02A, NHS02Ar, COOR<6>, CON(R<6>)2, CONHAr, COR<6>, COAr, S(0)nA eller S(0)nAr,
R<3>er A, sykloalkyl, -[C(R6) 2 ] n-Ar, -[C(R6)2 ]n-0 Ar,
~[C(R<6>)2]n-Het eller -C(R6)2=C(R6)2-Ar ,
R<6>er H, A eller benzyl,
X er fraværende, -CO-, -C(R<6>)2-, -C(R<6>)2-C (R<6>)2-, -C(R<6>)2-C0-, -C(R<6>)2-C(R<6>)2-C0-, -C(R6) 2= -C(R6)-CO-, -NR<6>CO-, -N{[C(R<6>)2]n<->COOR<6>}-CO- eller -C-(COOR<6>)R<6->C(R<6>)2-C0-,
Y er -C(R<6>)2-, -S02-, -CO-, -C00- eller -CONR<6->,
A er alkyl med 1-20 C-atomer, hvor én eller to e-grupper kan være erstattet med 0- eller S-atomer, eller med -CR<6>=CR<6>-grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, Ar', OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, NHCOAr', NHS02A, NHS02Ar',COOR<6>, CON(R<6>)2, CONHAr', COR<6>,COAr', S(0)nA eller S(0)nAr,
Ar' er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, OR<6>,N(R<6>)2, N02, CN,Hal, NHCOA, COOR<6>, CON(R<6>)2, COR<6>eller
S(0)nA,
Het er et mono- eller bisyklisk, mettet eller umettet heterosyklisk ringsystem som inneholder ett, to, tre eller fire identiske eller forskjellige heteroatomer, slik som nitrogen, oksygen og svovel, og som er usubstituert eller mono- eller polysubstituert med Hal, A, Ar', COOR<6>, CN, N(R<6>)2, N02, Ar-CONH-CH2
og/eller kabonyloksygen,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2,
og salter derav.
Oppfinnelsen tilveiebringer også de optisk aktive formene, racematene, diastereomerene og hydratene og solvatene av disse forbindelsene.
Oppfinnelsen var basert på det formål å oppdage nye forbindelser med verdifulle egenskaper, særlig de som kan anvendes til fremstilling av medikamenter.
Det er blitt funnet at forbindelsene med formel I og deres salter har svært anvendbare farmakologiske egenskaper,
koblet med god tolererbarhet. De har særlig faktor Xa-inhiberende egenskaper og kan derfor anvendes til å bekjempe og forhindre tromboemboliske forstyrrelser, slik som trombose, myokardinfarkt, arteriosklerose, betennelser, apopleksi, angina
pectoris, restenose etter angioplasti og claudiocatio intermittens.
Aromatiske amidinderivater med antitrombotisk virk-ning er kjent f.eks. fra EP 0 540 051 Bl. Sykliske guanidiner for behandling av tromboemboliske forstyrrelser er beskrevet f.eks. i WO 97/08165. Aromatiske, heterosykliske forbindelser med faktor Xa-inhiberende aktivitet er kjent f.eks. fra WO 96/10022.
Antitrombose- og antikoagulasjonseffektene av forbindelsene ifølge oppfinnelsen tilskrives inhiberingsvirkningen på den aktiverte koagulasjonsprotease, kjent under navnet faktor Xa. Faktor Xa er en av proteasene som er involvert i den komplekse prosessen med blodkoagulasjon. Faktor Xa kata- lyserer omdannelsen av protrombin til trombin, som igjen bidrar til trombedannelse. En aktivering av trombin kan resul-tere i at tromboemboliske forstyrrelser oppstår. Inhibering av faktor Xa kan således forhindre trombedannelse. Forbindelsene med formel I ifølge oppfinnelsen og deres salter griper inn i blodkoagulasjonsprosessen ved å inhibere faktor Xa, og inhiberer således dannelsen av tromber.
Inhiberingen av faktor Xa ved hjelp av forbindelsene ifølge oppfinnelsen og måling av antikoagulasjons- og anti-tromboseaktiviteten kan bestemmes ved hjelp av vanlige metoder in vitro eller in vivo. En egnet metode er beskrevet f.eks. av J. Hauptmann et al. i Thrombosis and Haemostasis, 63, 220-223
(1990) .
Inhiberingen av faktor Xa kan bestemmes f.eks. ved hjelp av metoden til T. Hara et al. i Thromb. Haemostas., 71, 314-319 (1994) .
Forbindelsene med formel I kan anvendes som medikamenter innen human- og veterinærmedisinen, særlig for bekjempelse og forhindring av tromboemboliske forstyrrelser, slik som trombose, myokardinfarkt, arteriosklerose, betennelser, apopleksi, angina pectoris, restenose etter angioplasti og claudiocatio intermittens.
Oppfinnelsen tilveiebringer forbindelsene med formel I og deres salter, og også en fremgangsmåte for fremstilling av forbindelsene med formel I ifølge krav 1 og deres salter, kjennetegnet ved at
a) de frigjøres fra et av sine funksjonelle derivater ved behandling med et solvolyserings- eller hydrogenolyseringsmiddel, ved
i) frigjøring av en amidinogruppe fra dens oksadiazolderivat ved hydrogenolyse,
ii) erstatning av en vanlig aminobeskyttelsesgruppe ved behandling med et solvolyserings- eller hydrogenolyseringsmiddel med hydrogen, eller frigjøring av en aminogruppe som er beskyttet av
en vanlig beskyttelsesgruppe,
eller
b) for fremstilling av forbindelser med formel I hvor R<1>er
X er -CO- eller -C(R<5>)2-CO-,
ogR<2>, R3 og Y er som definert i krav 1, en forbindelse med formel II
hvorR<3>,R4,R<5>, W og Y er som definert i krav 1, omsettes med en forbindelse med formel III hvor R<1>er
X er -CO- eller -C(R<6>)2-CO-,
ogR<2>er som definert i krav 1,
og L er Cl, Br, I eller en fri eller reaktiv,
funksjonelt derivatisert OH-gruppe,
eller
c) for fremstilling av forbindelser med formel I hvor R<1>er
Y er -S02-, -CO-, -C00- eller -C(R<6>)2-, ogR<2>og X er som definert i krav 1, en forbindelse med formel IV
hvor Y er -S02~, -CO-, -COO- eller -C(R<6>)2-,R<3>er som definert i krav 1,
og L er Cl, Br, I eller en fri eller reaktiv, funksjonelt derivatisert OH-gruppe,
omsettes med en forbindelse med formel V
hvor R<1>er
ogR<2>og X er som definert i krav 1,
eller
d) for fremstilling av forbindelser med formel I hvor R<1>er
Y er -CONH-,
ogR<2>og X er som definert i krav 1,
en forbindelse med formel VI
hvor R<3>er som definert i krav 1, omsettes med en forbindelse med formel V hvor R<1>er
ogR<2>og X er som definert i krav 1,
eller
e) for fremstilling av forbindelser med formel I hvor R<1>er -C(=NH)-NH2,
omdannes en cyangruppe til en amidinogruppe, og/eller
f) i en forbindelse med formel I omdannes ett eller flere radikalerR<1>, R<2>og/eller R<3>til ett eller
flere radikalerR<1>,R<2>og/eller R<3>, f.eks. ved i) hydrolyse av en estergruppe til en karboksylgruppe,
ii) reduksjon av en nitrogruppe eller
iii) acylering av en aminogruppe,
og/eller
g) en base eller syre med formel I omdannes til et av dens salter.
For alle radikalene som opptrer flere ganger, slik som f.eks. R<6>, er betydningene derav uavhengige av hverandre.
Ovenfor og nedenunder har radikalene eller para-metrene L, X, Y,R1,R<2>ogR<3>betydningene som er angitt for formlene I-VI, med mindre noe annet er uttrykkelig angitt.
I formlene ovenfor er A alkyl og har 1-20, fortrinnsvis 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 eller 12 C-atomer. A er fortrinnsvis for metyl, dessuten etyl, propyl, isopropyl, butyl, isobutyl, sek.-butyl eller tert.-butyl, dessuten også pentyl, 1-, 2- eller 3-metylbutyl, 1,1-, 1,2- eller 2,2-di-metylpropyl, 1-etylpropyl, heksyl, 1-, 2-, 3- eller 4-metyl-pentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- eller 3,3-dimetylbutyl, 1- eller 2-etylbutyl, 1-etyl-l-metylpropyl, l-etyl-2-metylpropyl, 1,1,2- eller 1,2,2-trimetylpropyl, heptyl, oktyl, nonyl eller decyl. Alkyl er dessuten f.eks. trifluormetyl, pentafluoretyl, allyl eller krotyl.
Sykloalkyl er fortrinnsvis syklopropyl, syklobutyl, syklopentyl, sykloheksyl eller sykloheptyl. Sykloalkyl er særlig radikalet av et bisyklisk terpen, slik som f.eks. 3-mentyl; idet særlig preferanse er gitt til kamfer-10-yl-radikalet.
COR<6>er acyl og er fortrinnsvis formyl, acetyl, propionyl, dessuten også butyryl, pentanoyl eller heksanoyl.
Hal er fortrinnsvis F, Cl eller Br, men også I.
R<2>er fortrinnsvis H, fluor, klor, brom, jod, hydroksyl, metoksy, etoksy, propoksy, nitro, amino, metylamino, dimetylamino, etylamino, dietylamino, acetamido, sulfonamido, metylsulfonamido, fenylsulfonamido, metyltio, etyltio, metylsulfinyl, etylsulfinyl, metylsulfonyl, etylsulfonyl, fenylsulfinyl, fenylsulfonyl, cyan, karboksyl, metoksykarbonyl, etoksykarbonyl, dessuten også acyl eller benzoyl.
R<3>er fortrinnsvis f.eks. A, sykloalkyl, Ar, -CH2Ar,
-CH20Ar, -CH2CH2Ar, -CH2Het, -CH2CH2Het eller -CH=CH-Ar.
R<6>er H, A eller benzyl, men fortrinnsvis H.
X er fortrinnsvis f.eks. fraværende, -CO-, -CH2-, -CH2-CH2-, -CH2-CO-, -CH2-CH2-CO-, -CH=CH~CO-, -NR<6>C0-, -N-{[CH2]n-COOR<6>}-CO- eller -CH(COOR6 )-CH2-CO-.
Y er fortrinnsvis f.eks. -S02- eller -CO-, dessuten også -COO-, -CONH- eller -CH2-.
Ar er fortrinnsvis usubstituert fenyl eller naftyl, dessuten foretrukket naftyl eller fenyl som er mono-, di-eller trisubstituert, f.eks. med A, fluor, klor, brom, jod, hydroksyl, metoksy, etoksy, propoksy, butoksy, pentyloksy, heksyloksy, benzyloksy, fenetyloksy, metyltio, etyltio, metyl-sulf inyl, etylsulfinyl, metylsulfonyl, etylsulfonyl, fenyl-sulf inyl, fenylsulfonyl, nitro, amino, metylamino, etylamino, dimetylamino, dietylamino, formamido, acetamido, propionyl-amino, butyrylamino, metylsulfonamido, etylsulfonamido, propylsulfonamido, butylsulfonamido, fenylsulfonamido, (4-metylfenyl)sulfonamido, karboksymetoksy, karboksyetoksy, metoksykarbonylmetoksy, metoksykarbonyletoksy, hydroksy-metoksy, hydroksyetoksy, metoksyetoksy, karboksyl, metoksykarbonyl, etoksykarbonyl, cyan, fenylaminokarbonyl, acyl eller benzoyl, dessuten også bifenyl.
Ar er derfor fortrinnsvis f.eks. o-, m- eller p-tolyl, o-, m- eller p-etylfenyl, o-, m- eller p-propylfenyl, o-, m- eller p-isopropylfenyl, o-, m- eller p-tert.-butyl-fenyl, o-, m- eller p-hydroksyfenyl, o-, m- eller p-nitrofenyl, o-, m- eller p-aminofenyl, o-, m- eller p-(N-metylamino)fenyl, o-, m- eller p-acetamidofenyl, o-, m- eller p-metoksyfenyl, o-, m- eller p-etoksyfenyl, o-, m- eller p-karboksyfenyl, o-, m- eller p-metoksykarbonylfenyl, o-, m-eller p-(N,N-dimetylamino)fenyl, o-, m- eller p-(N-etylamino)-fenyl, o-, m- eller p-(N,N-dietylamino)fenyl, o-, m- eller p-acetylfenyl, o-, m- eller p-formylfenyl, o-, m- eller p-fluorfenyl, o-, m- eller p-bromfenyl, o-, m- eller p-klorfenyl, o-, m- eller p-metylsulfonylfenyl, o-, m- eller p-(fenylsulfonamido)fenyl, o-, m- eller p-(metylsulfonamido)fenyl, o-, m-eller p-metyltiofenyl, dessuten fortrinnsvis 2,3-, 2,4-, 2,5-, 2,6-, 3,4- eller 3,5-difluorfenyl, 2,3-, 2,4-, 2,5-, 2,6-,
3.4- eller 3,5-diklorfenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- eller 3.5- dibromfenyl, 2,4- eller 2,5-dinitrofenyl, 2,5- eller 3,4-dimetoksyfenyl, 3-nitro-4-klorfenyl, 3-amino-4-klor-, 2-amino-3-klor-, 2-amino-4-klor-, 2-amino-5-klor- eller 2-amino-6-klorfenyl, 2-nitro-4-N,N-dimetylamino- eller 3-nitro-4-N,N-dimetylaminofenyl, 2,3-diaminofenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- eller 3,4,5-triklorfenyl, 2,4,6-trimetoksyfenyl, 2-hydroksy-3,5-diklorfenyl, p-jodfenyl, 3,6-diklor-4-aminofenyl,
4-fluor-3-klorfenyl, 2-fluor-4-bromfenyl, 2,5-difluor-4-bromfenyl, 3-brom-6-metoksyfenyl, 3-klor-6-metoksyfenyl, 3-klor-4-acetamidofenyl, 3-fluor-4-metoksyfenyl, 3-amino-6-metylfenyl, 3-klor-4-acetamidofenyl eller 2,5-dimetyl-4-klorfenyl.
Ar er svært særlig foretrukket usubstituert fenyl eller naftyl, dessuten fortrinnsvis f.eks. fenyl eller naftyl som er mono-, di- eller trisubstituert med A, klor, metoksy, amino eller dimetylamino, eller er dessuten også bifenyl.
Ar' er særlig f.eks. fenyl eller naftyl, dessuten foretrukket f.eks. o-, m- eller p-tolyl, o-, m- eller p-etylfenyl, o-, m- eller p-propylfenyl, o-, m- eller p-isopropylfenyl, o-, m- eller p-tert.-butylfenyl, o-, m- eller p-hydroksyfenyl, o-, m- eller p-nitrofenyl, o-, m- eller p-aminofenyl, o-, m- eller p-(N-metylamino)fenyl, o-, m- eller p-acetamidofenyl, o-, m- eller p-metoksyfenyl, o-, m- eller p-etoksyfenyl, o-, m- eller p-karboksyfenyl, o-, m- eller p-metoksykarbonylfenyl, o-, m- eller p-(N,N-dimetylamino)fenyl, o-, m- eller p-(N-etylamino)fenyl, o-, m- eller p-(N,N-dietylamino)fenyl, o-, m- eller p-acetylfenyl, o-, m- eller p-formylfenyl, o-, m- eller p-fluorfenyl, o-, m- eller p-bromfenyl, o-, m- eller p-klorfenyl, eller o-, m- eller p-metylsulfonylfenyl.
Het er fortrinnsvis f.eks. 2- eller 3-furyl, 2- eller 3- tienyl, 1-, 2- eller 3-pyrrolyl, 1-, 2-, 4- eller 5-imid-azolyl, 1-, 3-, 4- eller 5-pyrazolyl, 2-, 4- eller 5-oksazol-yl, 3-, 4- eller 5-isoksazolyl, 2-, 4- eller 5-tiazolyl, 3-, 4- eller 5-isotiazolyl, 2-, 3- eller 4-pyridyl, 2-, 4-, 5-eller 6-pyrimidinyl, videre foretrukket 1,2,3-triazol-l-, -4-eller -5-yl, 1,2,4-triazol-l-, -3- eller -5-yl, 1- eller 5-tetrazolyl, 1,2,3-oksadiazol-4- eller -5-yl, 1,2,4-oksadiazol-3- eller -5-yl, 1,3,4-tiadiazol-2- eller -5-yl, 1,2,4-tia-diazol-3- eller -5-yl, 1,2,3-tiadiazol-4- eller -5-yl, 3-eller 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- eller 7-indolyl, 4- eller 5-isoindolyl, 1-, 2-, 4- eller 5-benzimid-azolyl, 1-, 3-, 4-, 5-, 6- eller 7-benzopyrazolyl, 2-, 4-, 5-, 6- eller 7-benzoksazolyl, 3-, 4-, 5-, 6- eller 7-benzisoksa-zolyl, 2-, 4-, 5-, 6- eller 7-benzotiazolyl, 2-, 4-, 5-, 6-eller 7-benzisotiazolyl, 4-, 5-, 6- eller 7-benz-2,1,3-oksa-diazolyl, 2-, 3-, 4-, 5-, 6-, 7- eller 8-kinolyl, 1-, 3-, 4-, 5- , 6-, 7- eller 8-isokinolyl, 3-, 4-, 5-, 6-, 7- eller 8-cinnolinyl, 2-, 4—, 5-, 6-, 7- eller 8-kinazolinyl, 5- eller 6- kinoksalinyl, 2-, 3-, 5-, 6-, 7- eller 8-2H-benzo[1,4]oksa-zinyl, dessuten foretrukket 1,3-benzodioksol-5-yl, 1,4-benzo-dioksan-6-yl, 2,1,3-benzotiadiazol-4- eller -5-yl, 2,1,3-benz-oksadiazol-5-yl eller dibenzofuranyl.
De heterosykliske radikalene kan også være delvis eller fullstendig hydrogenert.
Het kan også være f.eks. 2,3-dihydro-2-, -3-, -4-eller -5-furyl, 2,5-dihydro-2-, -3-, -4- eller -5-furyl, tetrahydro-2- eller -3-furyl, 1,3-dioksolan-4-yl, tetrahydro-2- eller -3-tienyl, 2,3-dihydro-l-, -2-, -3-, -4- eller -5-pyrrolyl, 2,5-dihydro-l-, -2-, -3-, -4- eller -5-pyrrolyl, 1-, 2- eller 3-pyrrolidinyl, tetrahydro-1-, -2- eller -4-imidazol-yl, 2,3-dihydro-l-, -2-, -3-, -4- eller -5-pyrazolyl, tetrahydro-1-, -3- eller -4-pyrazolyl, 1,4-dihydro-l-, -2-, -3-eller -4-pyridyl, 1,2,3,4-tetrahydro-l-, -2-, -3-, -4-, -5-eller -6-pyridyl, 1-, 2-, 3- eller 4-piperidinyl, 2-, 3- eller 4-morfolinyl, tetrahydro-2-, -3- eller -4-pyranyl, 1,4-di-oksanyl, 1,3-dioksan-2-, -4- eller -5-yl, heksahydro-1-, -3-eller -4-pyridazinyl, heksahydro-1-, -2-, -4- eller -5-pyrimidinyl, 1-, 2- eller 3-piperazinyl, 1,2,3,4-tetrahydro-l-, -2-, -3-, -4-, -5-, -6-, -7- eller -8-kinolyl, 1,2,3,4-tetrahydro-l-, -2-, -3-, -4-, -5-, -6-, -7- eller -8-isokinolyl, 2-, 3-, 5-, 6-, 7- eller 8-3,4-dihydro-2H-benzo[1,4]oksazinyl, dessuten foretrukket 2,3-metylendioksyfenyl, 3,4-metylendioksyfenyl, 2,3-etylendioksyfenyl, 3,4-etylendioksyfenyl, 3,4-(difluormetylendioksy)fenyl, 2,3-dihydrobenzofuran-5-eller -6-yl, 2,3-(2-oksometylendioksy)fenyl, eller ellers 3,4-dihydro-2H-l,5-benzodioksepin-6- eller -7-yl, dessuten foretrukket 2,3-dihydrobenzofuranyl eller 2,3-dihydro-2-oksofuran-yl.
Het er usubstituert mono- eller polysubstituert med Hal, A, Ar', COOR<6>,CN, N(R<6>)2, N02, Ar-CONH-CH2. "Poly" betyr di, tri, tetra eller penta.
Forbindelsene med formel I kan ha ett eller flere kirale sentre, og kan derfor være til stede i forskjellige stereoisomere former. Formel I omfatter alle disse formene.
Oppfinnelsen tilveiebringer følgelig særlig de forbindelsene med formel I hvor minst ett av de ovenfor nevnte radikaler har én av de foretrukne betydninger som er angitt ovenfor. Noen foretrukne grupper av forbindelser kan uttrykkes ved hjelp av de følgende rester Ia-If, som tilsvarer formel I, og hvor radikalene som ikke er definert nærmere, har betyd-ningen angitt for formel I, men hvor
i Ia R<1>er -C(=NH)-NH2, som også kan være monosubstituert med -COA, -CO-[C(R6 ) 2 ] n~Ar, -COOA, -0H eller med en vanlig aminobeskyttelsesgruppe,
R<2>er H, A, OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA,
NHCOAr, NHS02A, NHS02Ar, COOR<6>, CON(R<6>)2, CONHAr, COR<6>, COAr, S(0)nA eller S(0)nAr,
R<3>er A, sykloalkyl, Ar, -CH2Ar, -CH2OAr, -CH2-CH2Ar, -CH2Het, -CH2CH2Het eller -CH=CH-Ar,
R<6>er H eller A,
X er fraværende, -CO-, -CH2-CO-, -CH2-CH2-CO-, -CH2-, -CH2-CH2-, -CH=CH-CO-, -NHCO-, -N(CH2-COOR<6>)-CO- eller -CH(COOR<6>)-CH2-CO-,
Y er -S02-, -CO-, -C00-, -CO-NH- eller -CH2-,
A er alkyl med 1-20 C-atomer, hvor én eller to CH2-grupper kan være erstattet med O- eller S-atomer, eller med -CR<6>=CR<6>-grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, Ar<1>, OR<6>, N(R<5>)2, N02, CN, Hal, NHCOA, NHCOAr', NHS02A, NHS02Ar', COOR6, CON(R<6>)2, CONHAr',COR<6>, COAr', S(0)nA eller S(0)nAr,
Ar' er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, COOR<6>, CON(R<6>)2, COR<6>éller S(0)nA,
Het er et mono- eller bisyklisk, mettet eller umettet heterosyklisk ringsystem som inneholder ett, to, tre eller fire identiske eller forskjellige heteroatomer, slik som nitrogen, oksygen og svovel, og som er usubstituert eller mono- eller polysubstituert med Hal, A, Ar', COOR<6>, CN, N(R<6>)2, N02, Ar-CONH-CH2og/eller kabonyloksygen,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2;
i Ib R<1>er -C(=NH)-NH2, som også kan være monosubstituert med -COA, -CO-[C(R<6>)2]n-Ar, -COOA, -OH eller med en vanlig aminobeskyttelsesgruppe,
R<2>er H,
R<3>er A, sykloalkyl, Ar, -CH2Ar, -CH20Ar, -CH2-CH2Ar, -CH2Het, -CH2CH2Het eller -CH=CH-Ar,
R<6>er H eller A,
X er fraværende, -CO-, -CH2-C0-, -CH2-CH2-CO-, -CH2-, -CH2-CH2-, -CH=CH-CO-, -NHCO-, -N(CH2-COOR<6>)-CO- eller -CH(COOR<6>)-CH2-CO-,
Y er -S02-, -CO-, -C00-, -CO-NH- eller -CH2-,
A er alkyl med 1-20 C-atomer, hvor én eller to CH2-grupper kan være erstattet med 0- eller S-atomer, eller med -CR<6>=CR<6>-grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, Ar', OR<6>, NH2, N02, CN, Hal, NHCOA, NHCOAr', NHS02A, NHS02Ar', COOR<6>, CON(R<6>)2/CONHAr', COR<6>, CO-Ar', S(0)nA eller S(0)nAr,
Ar' er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, COOR<6>, CON(R<6>)2, COR<6>eller S(0)nA,
Het er et mono- eller bisyklisk, mettet eller umettet heterosyklisk ringsystem som inneholder ett, to, tre eller fire identiske eller forskjellige heteroatomer, slik som nitrogen,, oksygen og svovel, og som er usubstituert eller mono- eller polysubstituert med Hal, A, Ar', COOR<6>, CN, N(R<6>)2, N02/Ar-CONH-CH2og/eller kabonyloksygen,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2;
iIc R<1>er -C(=NH)-NH2, som også kan være monosubstituert med -COA, -CO-[C(R6) 2 ] n-Ar, -COOA, -OH eller med en vanlig aminobeskyttelsesgruppe,
R<2>er H,
R<3>er A, sykloalkyl, Ar, -CH2Ar, -CH2OAr, -CH2~
CH2Ar, -CH2Het, -CH2CH2Het eller -CH=CH-Ar,
R<6>er H eller A,
X er fraværende, -CO-, -CH2-CO-, -CH2-CH2-CO-, -CH2-, -CH2-CH2-, -CH=CH-CO-, -NHCO-, -N{CH2-COOR<6>}-CO- eller -CH(COOR<6>)-CH2-CO-,
Y er -S02-, -CO-, -COO-, -CO-NH- eller -CH2-,
A er alkyl med 1-20 C-atomer, hvor én eller to CH2-grupper kan være erstattet med O- eller S-atomer, eller med -CR<6>=CR<6>-grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, Ar', OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, NHCOAr', NHS02A, NHS02Ar', COOR<6>, CON(R<6>)2, CONHAr', COR<6>, COAr', S(0)nA eller S(0)nAr,
Ar' er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, COOR6, CON(R<6>)2, COR<6>eller S(0)nA,
Het er et mono- eller bisyklisk, heterosyklisk ringsystem som er usubstituert eller mono- eller polysubstituert med Hal, A,Ar", COOR<6>, CN, N(R<6>)2, NO2, Ar-CONH-CH2og/eller kabonyloksygen, valgt fra gruppen bestående av tiofen, tetrahydrokinolin, kroman, pyrazol, isoksazol, pyridin, benzodioksol eller benzotiofen,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2;
i Id R<1>er -C(=NH)-NH2/som også kan være monosubstituert med -COA, -CO-[C(R<6>)2]n~Ar, -COOA, -OH eller med en vanlig aminobeskyttelsesgruppe,
R<2>er H,
R<3>er A, sykloalkyl, Ar, -CH2Ar, -CH2OAr, -CH2-CH2Ar, -CH2Het, -CH2CH2Het eller -CH=CH-Ar,
R<6>er H eller A,
X er fraværende, -CO-, -CH2-CO-, -CH2-CH2-CO-, -CH2-, -CH2-CH2-, -CH=CH-CO-, -NHCO-, -N{CH2~COOR<6>}-CO- eller -CH(COOR<6>)-CH2-CO-,
Y er -S02-, -CO-, -CO-NH- eller -CH2-,
A er alkyl med 1-20 C-atomer, hvor én eller to CH2-grupper kan være erstattet med O- eller S-atomer, eller med -CR<6>=CR<6>-grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, Ar", OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, NHCOAr', NHS02A, NHS02Ar', COOR6, CON(R<6>)2, CONHAr', COR6, COAr', S(0)nA eller S(0)nAr,
Ar' er fenyl,
Het er et mono- eller bisyklisk, heterosyklisk ringsystem som er usubstituert eller mono- eller polysubstituert med Hal, A, Ar', COOR<6>,CN, N(R<6>)2, NO2 1 Ar-CONH-CH2og/eller kabonyl oksygen, valgt fra gruppen bestående av tiofen, tetrahydrokinolin, kroman, pyrazol, isoksazol, pyridin, benzodioksol, benzotiofen eller dibenzofuran,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2;
i le R<1>er -C(=NH)-NH2/som også kan være monosubstituert med -COA, -CO-[C(R<6>)2]n-Ar, -C00A, -OH eller med en vanlig aminobeskyttelsesgruppe,
R<2>er H,
R<3>er A, sykloalkyl, Ar, -CH2Ar, -CH2OAr, -CH2-CH2Ar, -CH2Het, -CH2CH2Het eller -CH=CH-Ar,
R<6>er H eller A,
X er fraværende, -CO-, -CH2-CO-, -CH2-CH2-CO-, -CH2-, -CH2-CH2-, -NHCO-, -N{CH2-COOR<6>}-C0-eller -CH(COOR<6>)-CH2-C0-,
Y er -S02-, -CO- eller -CH2-,
A er alkyl med 1-20 C-atomer, hvor én eller to CH2-grupper kan være erstattet med 0- eller S-atomer, eller med -CR<6>=CR<6>-grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, Ar', OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, NHCOAr', NHS02A, NHS02Ar', COOR<6>, CON(R<6>)2, CONHAr",COR<6>, COAr", S(0)nA eller S(0)nAr,
Ar' er fenyl,
Het er et mono- eller bisyklisk, heterosyklisk ringsystem som er usubstituert eller mono- eller polysubstituert med Hal, A,Ar', COOR<6>,CN, N(R<6>)2, N02, Ar-CONH-CH2og/eller kabonyloksygen, valgt fra gruppen bestående av tiofen, tetrahydrokinolin, kroman, pyrazol, isoksazol, pyridin, benzodioksol, benzotiofen eller dibenzofuran,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2;
i If R<1>er -C(=NH)-NH2, som også kan være monosubstituert med -COA,
R<2>er H,
R<3>er A, sykloalkyl, Ar, -CH2Ar, -CH20Ar, -CH2-CH2Ar, -CH2Het, -CH2CH2Het eller -CH=CH-Ar,
R<6>er H eller A,
X er fraværende, -CO-, -CH2-C0-, -CH2-CH2-CO-, -CH2-, -CH2-CH2-, -NHCO-, -N{CH2-COOR<6>}-CO-eller -CH(COOR<6>)-CH2-CO-,
Y er -S02-, -CO- eller -CH2-,
A er alkyl med 1-20 C-atomer, hvor én eller to CH2-grupper kan være erstattet med 0- eller S-atomer, eller med -CR<6>=CR<6>-grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller mono-, di- eller trisubstituert med A, Ar', OR<6>, N(R<6>)2, N02, CN, Hal, NHCOA, NHCOAr', NHS02A, NHS02Ar', COOR6, C0N(R<6>)2, CONHAr', COR<6>, COAr', S(0)nA eller S(0)nAr,
Ar' er fenyl,
Het er et mono- eller bisyklisk, heterosyklisk ringsystem som er usubstituert eller mono- eller polysubstituert med Hal, A, Ar', COOR<6>,CN, N(R<6>)2, N02, Ar-CONH-CH2og/eller kabonyloksygen, valgt fra gruppen bestående av tiofen, tetrahydrokinolin, kroman, pyrazol, isoksazol, pyridin, benzodioksol, benzotiofen eller dibenzofuran,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2.
Forbindelsene med formel I og også utgangsmaterialene for deres fremstilling fremstilles ellers ved hjelp av fremgangsmåter som er i og for seg kjente, slik som de er beskrevet i litteraturen (f.eks. i standardverkene, slik som Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), og særlig under de reaksjonsbetingelsene som er kjent og egnet for de nevnte reaksjoner. Ved disse reaksjonene kan det også benyttes varianter som er i og for seg kjente, og som her ikke er nærmere nevnt.
Om ønsket kan utgangsmaterialene også dannes in situ, slik at de ikke isoleres fra reaksjonsblandingen, men omsettes videre umiddelbart, hvorved man får forbindelsene med formel
I.
Forbindelser med formel I kan fortrinnsvis fås ved å frigjøre forbindelsene med formel I fra et av deres funksjonelle derivater ved behandling med et solvolyserings- eller hydrogenolyseringsmiddel.
Foretrukne utgangsmaterialer for solvolysen eller hydrogenolysen er de som ellers tilsvarer formel I, men som i stedet for én eller flere frie amino- og/eller hydroksylgrupper inneholder tilsvarende beskyttede amino- og/eller hydroksylgrupper, fortrinnsvis de som i stedet for et H-atom som er bundet til et N-atom bærer en aminobeskyttelsesgruppe, særlig de som i stedet for en HN-gruppe bærer en R'-N-gruppe, hvor R' er en aminobeskyttelsesgruppe, og/eller de som i stedet for H-atomet i en hydroksylgruppe bærer en hydroksylbeskyttelsesgruppe, f.eks. de som tilsvarer formel I, men som i stedet for en -COOH-gruppe bærer en gruppe -COOR'', hvor R'' er en hydroksylbeskyttelsesgruppe.
Foretrukne utgangsmaterialer omfatter også oksa-diazolderivatene, som kan omdannes til de tilsvarende amidino-forbindelser.
Innføringen av oksadiazolgruppen utføres f.eks. ved å omsette cyanforbindelsene med hydroksylamin og omsetning med fosgen, dialkylkarbonat, klormaursyreester, N,N'-karbonyl-diimidazol eller eddiksyreanhydrid.
Det er også mulig for flere, identiske eller forskjellige, beskyttede amino- og/eller hydroksylgrupper å være til stede i molekylet til utgangsmaterialet. Dersom beskyt-telsesgruppene som er til stede atskiller seg fra hverandre, kan de i mange tilfeller avspaltes selektivt.
Uttrykket "aminobeskyttelsesgruppe" er generelt kjent og henviser til grupper som er egnet for beskyttelse (blok-kering) av en aminogruppe mot kjemiske reaksjoner, men som lett kan fjernes etter at den ønskede kjemiske reaksjon er blitt utført på andre steder i molekylet. Typiske slike grupper er særlig usubstituerte eller substituerte acyl-, aryl-, aralkoksymetyl- eller aralkylgrupper. Ettersom amino-beskyttelsesgruppene fjernes etter den ønskede omsetning
(eller reaksjonsrekkefølge), er deres type og størrelse ellers ikke av avgjørende betydning; de som har 1-2 0, særlig 1-8, C-atomer er imidlertid foretrukket. Uttrykket "acylgruppe" skal fortolkes i sin bredeste betydning i forbindelse med fore-liggende fremgangsmåte. Det omfatter acylgrupper avledet fra alifatiske, aralifatiske, aromatiske eller heterosykliske karboksylsyrer eller sulfonsyrer, og særlig alkoksykarbonyl-, aryloksykarbonyl- og fremfor alt aralkoksykarbonylgrupper. Eksempler på slike acylgrupper er alkanoyl, slik som acetyl, propionyl eller butyryl; aralkanoyl, slik som fenylacetyl; aroyl, slik som benzoyl eller toluyl; aryloksyalkanoyl, slik som POA; alkoksykarbonyl, slik som metoksykarbonyl, etoksykarbonyl, 2,2,2-trikloretoksykarbonyl, BOC (tert.-butyloksy-karbonyl), 2-jodetoksykarbonyl; aralkyloksykarbonyl, slik som CBZ("karbobenzoksy"), 4-metoksybenzyloksykarbonyl, FMOC; arylsulfonyl, slik som Mtr. Foretrukne aminobeskyttelses-grupper er BOC og Mtr, og dessuten CBZ, Fmoc, benzyl og acetyl.
Uttrykket "hydroksylbeskyttelsesgruppe" er også generelt kjent og henviser til grupper som er egnet for beskyttelse av en hydroksylgruppe mot kjemiske omsetninger, men som lett kan fjernes etter at den ønskede kjemiske reaksjon er blitt utført på andre steder i molekylet. Typiske slike grupper er de ovenfor nevnte usubstituerte eller substituerte aryl-, aralkyl- eller acylgrupper, og dessuten også alkylgrupper. Typen av og størrelsen til hydroksylbeskyttel-sesgruppene er ikke av avgjørende betydning, ettersom de fjernes igjen etter den ønskede kjemiske reaksjon eller reaksjonsrekkefølge; grupper med 1-20, særlig 1-10, C-atomer er foretrukket. Eksempler på hydroksylbeskyttelsesgrupper er blant annet benzyl, p-nitrobenzoyl, p-toluensulfonyl, tert.-butyl og acetyl, idet benzyl og tert.-butyl er særlig foretrukket .
Frigjøringen av forbindelsene med formel I fra deres funksjonelle derivater utføres, avhengig av eskyttelsesgruppen som anvendes, f.eks. med sterke syrer, hensiktsmessig med TFA eller perklorsyre, men også med andre sterke uorganiske syrer, slik som saltsyre eller svovelsyre; sterke organiske karboksylsyrer, slik som trikloreddiksyre; eller sulfonsyrer, slik som benzen- eller p-toluensulfonsyre. Tilstedeværelsen av et ytterligere inert oppløsningsmiddel er mulig, men ikke alltid nødvendig. Egnede inerte oppløsningsmidler er fortrinnsvis organiske oppløsningsmidler, f.eks. karboksylsyrer, slik som eddiksyre; etere, slik som tetrahydrofuran eller dioksan; amider, slik som DMF; halogenerte hydrokarboner, slik som diklormetan; eller dessuten også alkoholer, slik som metanol, etanol eller isopropanol; og vann. Blandinger av de ovenfor nevnte oppløsningsmidler er dessuten mulig. TFA anvendes fortrinnsvis i overskudd uten tilsetning av et ytterligere opp-løsningsmiddel, og perklorsyre anvendes i form av en blanding av eddiksyre og 70 % perklorsyre i et forhold på 9:1. Reaksjonstemperaturene for spaltingen er hensiktsmessig mellom ca. 0 og ca. 50 °C, og reaksjonen utføres fortrinnsvis ved mellom 15 og 30 °C (romtemperatur).
Gruppene BOC, OBut og Mtr kan fortrinnsvis avspaltes f.eks. med TFA i diklormetan, eller med ca. 3-5 N HCl i dioksan ved 15-30 °C, og Fmoc-gruppen kan avspalttes med en omtrent 5-50 % oppløsning av dimetylamin, dietylamin eller piperidin i DMF ved 15-30 °C.
Beskyttelsesgrupper som kan fjernes ved hjelp av hydrogenolyse (f.eks. CBZ, benzyl eller frigjøringen av amidinogruppen fra dens oksadiazolderivat) kan avspaltes f.eks. ved behandling med hydrogen i nærvær av en katalysator (f.eks. en edelmetallkatalysator, slik som palladium, hensiktsmessig på en bærer, slik som karbon). Egnede oppløsnings-midler for denne reaksjonen er dem nevnt ovenfor, særlig f.eks. alkoholer, slik som metanol eller etanol; eller amider, slik som DMF. Hydrogenolysen gjennomføres generelt ved temperaturer mellom ca. 0 og 100 °C under trykk mellom ca. 1 og 200 bar, fortrinnsvis ved 20-30 °C og 1-10 bar. Hydrogenolyse av CBZ-gruppen utføres lett f.eks. på 5-10 % Pd-C i metanol, eller med ammoniumformiat (i stedet for hydrogen) på Pd/C i metanol/DMF ved 20-30 °C.
Forbindelser med formel I hvorR<1>er
X er -CO- eller -C(R<6>)2-CO-, og R<2>, R<3>og Y er som definert i krav 1, kan fortrinnsvis oppnås ved å omsette forbindelser med formel II med forbindelser med formel III.
I forbindelsene med formel III er L fortrinnsvis
Cl, Br, I eller en reaktivt modifisert OH-gruppe, slik som f.eks. en aktivert ester, et imidazolid eller alkylsulfonyl-
oksy med 1-6 C-atomer (fortrinnsvis metylsulfonyloksy), eller arylsulfonyloksy med 6-10 C-atomer (fortrinnsvis fenyl- eller p-tolylsulfonyloksy).
Omsetningen utføres generelt i et inert oppløsnings-middel i nærvær av et syrebindingsmiddel, fortrinnsvis et alkalimetallhydroksid, -karbonat eller -bikarbonat, eller et jordalkalimetallhydroksid, -karbonat eller -bikarbonat, eller et annet salt av en svak syre med alkalimetallene eller jord-alkalimetallene, fortrinnsvis kalium, natrium, kalsium eller cesium. Tilsetningen av en slik organisk base som trietylamin, dimetylanilin, pyridin eller kinolin, eller av et overskudd av aminkomponenten i formel II, eller alkyleringsderivatet med formel III, kan også være gunstig. Avhengig av betingelsene som anvendes, er reaksjonstiden mellom flere minutter og 14 dager, reaksjonstemperaturen er mellom omtrent 0 og 150 °C, vanligvis mellom -20 og 130 °C.
Egnede inerte oppløsningsmidler er f.eks. hydrokarboner, slik som heksan, petroleter, benzen, toluen eller xylen; klorerte hydrokarboner, slik som trikloretylen, 1,2-dikloretan, karbontetraklorid, kloroform eller diklormetan; alkoholer, slik som metanol, etanol, isopropanol, n-propanol, n-butanol eller tert.-butanol; etere, slik som dietyleter, diisopropyleter, tetrahydrofuran (THF) eller dioksan; glykol-etere, slik som etylenglykolmonometyl- eller -monoetyleter (metylglykol eller etylglykol), eller etylenglykoldimetyleter (diglym); ketoner, slik som aceton eller butanon; amider, slik som acetamid, dimetylacetamid, N-metylpyrrolidon (NMP) eller dimetylformamid (DMF); nitriler, slik som acetonitril; sulf-oksider, slik som dimetylsulfoksid (DMSO); karbondisulfid; karboksylsyrer, slik som maursyre eller eddiksyre; nitro-forbindelser, slik som nitrometan eller nitrobenzen; estere, slk som etylacetat; eller blandinger av de nevnte oppløsnings-midler .
Utgangsmaterialene med formlene II og III er generelt kjent. De som imidlertid er nye, kan fremstilles ved hjelp av i og for seg kjente fremgangsmåter.
Forbindelser med formel I hvor R1 er
Y er S02, CO eller C00, og R<2>og X er som definert i krav 1, kan fortrinnsvis fås ved å omsette forbindelser med formel IV med forbindelser med formel V.
I forbindelsene med formel IV er L fortrinnsvis Cl, Br, I eller en reaktivt modifisert OH-gruppe, slik som f.eks. en aktivert ester, et imidazolid eller alkylsulfonyloksy med 1-6 C-atomer (fortrinnsvis metylsulfonyloksy), eller arylsulfonyloksy med 6-10 C-atomer (fortrinnsvis.fenyl- eller p-tolylsulfonyloksy).
Omsetningen av forbindelsene med formel IV med forbindelser med formel V utføres fortrinnsvis i et inert opp-løsningsmiddel med tilsetning av en base og ved temperaturer som angitt ovenfor.
Utgangsmaterialene med formlene IV og V er generelt kjent. De som imidlertid er nye, kan fremstilles ved hjelp av i og for seg kjente fremgangsmåter.
Forbindelser med formel I hvorR<1>er
Y er CONH, og R<2>og X er som definert i krav 1, kan fortrinnsvis fås ved å omsette forbindelser med formel VI med forbindelser med formel V.
Omsetningen av forbindelsene med formel VI med forbindelser med formel V utføres fortrinnsvis i et inert opp-løsningsmiddel og ved temperaturer som angitt ovenfor.
Utgangsmaterialene med formel VI er generelt kjent. De som imidlertid er nye, kan fremstilles ved hjelp av i og for seg kjente fremgangsmåter.
Forbindelser med formel I hvor R1 er -C(=NH)-NH2, kan dessuten fås fra den tilsvarende cyanforbindelse.
Omdannelsen av en cyangruppe til en amidinogruppe ut-føres ved omsetning med f.eks. hydroksylamin og etterfølgende reduksjon av N-hydroksamidinet med hydrogen i nærvær av en slik katalysator som f.eks. PD/C.
For å fremstille et amidin med formel I (R<1>= -C-(=NH)-NH2) kan også ammoniakk tilsettes på et nitril med formel I (R<1>= CN). Tilsetningen utføres fortrinnsvis i flere stadier ved hjelp av en fremgangsmåte hvor, på en i og for seg kjent måte, a) nitrilet omdannes med H2S til et tioamid som omdannes med et alkyleringsmiddel, f.eks. CH3I, til den tilsvarende S-alkylimidotioester, som igjen omsettes med NH3, hvorved man får amidinet, b) nitrilet omdannes med en alkohol, f.eks. etanol, i nærvær av HC1 til den tilsvarende imidOester, og denne behandles med ammoniakk, eller c) nitrilet omsettes med litium-bis(trimetylsilyl)amid, og produktet hydrolyseres så.
Dessuten er det mulig å omdanne en forbindelse med formel I til en annen forbindelse med formel I ved omdannelse av ett eller flere radikalerR<1>,R<2>,R<3>,R<4>og/eller R<5>til ett eller flere radikaler R<1>, R<2>, R<3>,R4og/eller R<5>, f.eks. ved å redusere nitrogrupper (f.eks. ved hydrogenering over Raney-nikkel ellerPd/karbon i et inert oppløsningsmiddel, slik som metanol eller etanol) til aminogrupper.
Estere kan hydrolyseres f.eks. med eddiksyre eller NaOH eller KOH i vann, vann-THF eller vann-dioksan ved temperaturer mellom 0 og 100 °C.
Det er dessuten mulig å acylere frie aminogrupper på en vanlig måte med et acylklorid eller syreanhydrid, eller å alkylere med et usubstituert eller substituert alkylhalogenid, hensiktsmessig i et inert oppløsningsmiddel, slik som diklormetan eller THF, og/eller i nærvær av en base, slik som trietylamin eller pyridin, ved temperaturer mellom -60 og +30 °C.
En base med formel I kan omdannes til det ledsagende syreaddisjonssalt med en syre, f.eks. ved omsetning av ekvi-valente mengder av basen og syren i et inert oppløsnings-middel, slik som etanol, og etterfølgende inndamping. Syrer som gir fysiologisk akseptable salter, er særlig egnet for denne omsetningen. Det er således mulig å anvende uorganiske syrer, f.eks. svovelsyre, salpetersyre, hydrogenhalogensyrer, slik som saltsyre eller hydrobromsyre, fosforsyrer, slik som ortofosforsyre, eller sulfaminsyre, eller dessuten organiske syrer, særlig alifatiske, alisykliske, aralifatiske, aromatiske eller heterosykliske en- eller flerbasiske karboksylsyrer, sulfonsyrer eller svovelsyrer, f.eks. maursyre, eddiksyre, propionsyre, pivalinsyre, dietyleddiksyre, malonsyre, ravsyre, pimelinsyre, fumarsyre, maleinsyre, melkesyre, vinsyre, eplesyre, sitronsyre, glukonsyre, askorbinsyre, nikotin-syre, isonikotinsyre, metan- eller etansulfonsyre, etan-disulfonsyre, 2-hydroksyetansulfonsyre, benzensulfonsyre, p-toluensulfonsyre, naftalenmono- eller -disulfonsyrer, og laurylsvovelsyre. Salter med fysiologisk ikke akseptable syrer, f.eks. pikrater, kan anvendes til isolering og/eller rensing av forbindelsene med formel I.
På den annen side kan forbindelser med formel I omdannes med baser (f.eks. natriumhydroksid, kaliumhydroksid, natriumkarbonat eller kaliumkarbonat) til de tilsvarende metallsalter, særlig alkalimetall- eller jordalkalimetall-salter, eller til de tilsvarende ammoniumsalter.
På grunn av deres molekylstruktur kan forbindelsene med formel I ifølge oppfinnelsen være kirale og kan følgelig være til stede i forskjellige enantiomerformer. De kan derfor være til stede i racemisk eller i optisk aktiv form.
Ettersom den farmasøytiske aktivitet til racematene og/eller stereoisomerene av forbindelsene ifølge oppfinnelsen kan atskille seg fra hverandre, kan det være ønskelig å bruke enantiomerene. I disse tilfellene kan sluttproduktet eller til og med mellomproduktene separeres i enantiomerforbindelser under anvendelse av kjemiske eller fysikalske midler som er kjent for fagfolk innen teknikken, eller de kan til og med anvendes som sådanne i syntesen.
I tilfellet med racemiske aminer dannes diastereo-merer fra blandingen ved omsetning med et optisk aktivt separasjonsmiddel. Egnede separasjonsmidler er f.eks. optisk aktive syrer, slik som R- og S-formene av vinsyre, diacetyl-vinsyre, dibenzoylvinsyre, mandelsyre, eplesyre, melkesyre, passende N-beskyttede aminosyrer (f.eks. N-benzoylprolin eller N-benzensulfonylprolin) eller de forskjellige optisk aktive kamfersulfonsyrer. En kromatografisk separasjon av enantiomerene kan også med fordel utføres ved hjelp av et optisk aktivt separasjonsmiddel (f.eks. dinitrobenzoylfenylglysin, cellulosetriacetat eller andre karbohydratderivater eller kirale, derivatiserte metakrylatpolymerer som er immobilisert på silikagel. Oppløsningsmidler som er egnet for dette formål, er vandige eller alkoholiske oppløsningsmiddelblandinger, slik som f.eks. heksan/isopropanol/acetonitril, f.eks. i forholdet 82:15:3.
Oppfinnelsen tilveiebringer dessuten anvendelsen av forbindelsene med formel I og/eller deres fysiologisk akseptable salter til fremstilling av farmasøytiske preparater, særlig ved hjelp av en ikke-kjemisk vei. For dette formål kan de bringes i en egnet doseringsform sammen med minst én fast, flytende og/eller halvflytende bærer eller et hjelpestoff og, dersom det er passende, i kombinasjon med én eller flere ytterligere aktive forbindelser.
Oppfinnelsen tilveiebringer dessuten farmasøytiske preparater som omfatter minst én forbindelse med formel I og/eller et av dens fysiologisk akseptable salter.
Disse preparatene kan anvendes som medikamenter innen human- eller veterinærmedisinen. Mulige bærere er organiske eller uorganiske stoffer som er egnet for enteral (f.eks. oral), parenteral eller topisk administrering, og som ikke reagerer med de nye forbindelsene, f.eks. vann, vegetabilske oljer, benzylalkoholer, alkylenglykoler, polyetylenglykoler, glyseroltriacetat, gelatin, karbohydrater, slik som laktose eller stivelse, magnesiumstearat, talkum og vaselin. Tabletter, piller, belagte tabletter, kapsler, pulvere, granuler, siruper, safter eller dråper anvendes særlig for oral administrering, suppositorier anvendes for rektal administrering, oppløsninger, fortrinnsvis olje- eller vannoppløsninger, og dessuten suspensjoner, emulsjoner eller implantater anvendes til parenteral administrering, og salver, kremer eller pulvere anvendes til topisk administrering. De nye forbindelsene kan også lyofiliseres, og de resulterende lyofilisater kan anvendes f.eks. til fremstillingen av injeksjonspreparater. De nevnte preparater kan steriliseres og/eller omfatte hjelpe-stoffer, slik som smøremidler, konserveringsmidler, stabili-seringsmidler og/eller fuktemiddel, emulgeringsmidler, salter for påvirkning av det osmotiske trykk, bufferstoffer, farge-stoffer, smaksstoffer og/eller flere ytterligere aktive forbindelser, f.eks. ett eller flere vitaminer.
Forbindelsene med formel I og deres fysiologisk akseptable salter kan anvendes til bekjempelsen og forhindring av tromboemboliske forstyrrelser, slik som trombose, myokardinfarkt, arteriosklerose, betennelser, apopleksi, angina pectoris, restenose etter angioplasti og claudiocatio intermittens.
For dette formål administreres forbindelsene ifølge oppfinnelsen fortrinnsvis vanligvis ved doseringer mellom ca. 1 og 500 mg, særlig mellom 5 og 100 mg pr. doseringsenhet. Den daglige dosering er fortrinnsvis mellom ca. 0,02 og 10 mg/kg kroppsvekt. Den bestemte dose for hver pasient avhenger imidlertid av de mest forskjellige faktorer, f.eks. av aktivi-teten til den bestemte forbindelse som anvendes, av alderen, kroppsvekten, den generelle helsetilstand, kjønnet, kosten, administreringstiden og -veien, og av utskillingshastigheten, medikamentkombinasjonen og alvorligheten av den bestemte syk-dom som behandlingen gjelder for. Oral administrering er foretrukket .
Alle temperaturer ovenfor og nedenunder er angitt i
°C. I de etterfølgende eksempler betyr "vanlig opparbeidelse":
Om nødvendig tilsettes vann, om nødvendig bringes pH til
verdier mellom 2 og 10, avhengig av sluttproduktets struktur, blandingen ekstraheres med etylacetat eller diklormetan, den organiske fase fraskilles, tørkes over natriumsulfat og inn-dampes, og resten renses ved hjelp av kromatografi over silikagel og/eller krystallisasjon. Rf-verdier er for silikagel; mobil fase: etylacetat/metanol = 9:1.
Massespektrometri (MS):
EI (elektronstøtionisering) M<+>
FAB (hurtig atombombardement) (M+H)<+>.
Eksempel 1
4 6 ml tionylklorid og 1 ml DMF tilsettes til en opp-løsning av 10,0 g 4-(5-metyl-l,2,4-oksadiazol-3-yl)benzosyre i 150 ml toluen. Oppløsningen varmes opp under refluks i 5 timer. Oppløsningsmidlet fjernes, hvorved man får 4-(5-metyl-l,2,4-oksadiazol-3-yl)benzoylklorid, EI 222. Etter-følgende omsetning med 9,3 g 1-tert.-butoksykarbonylpiperazin i 150 ml diklormetan og 48 ml trietylamin gir etter vanlig opparbeidelse tert.-butyl-4-[4-(5-metyl-[1,2,4]-oksadiazol-3-yl)benzoyl]piperazin-l-karboksylat, FAB 37 3.
BOC-gruppen avspaltes under anvendelse av 4 N HC1 i dioksan. En oppløsning av 100 mg av det resulterende [4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]piperazin-l-ylmetanon ("A")
og 120 mg 6-klornaftalen-2-sulfonylklorid i 5 ml diklormetan blandes med 400 mg 4-dimetylaminopyridin på polystyren, og blandingen omrøres ved romtemperatur i 18 timer. Filtrering og fjerning av oppløsningsmidlet gir [4-(6-klornaftalen-2-sulfo-nyl)piperazin-l-yl[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-metanon, FAB 497 .
På lignende måte gir omsetning av "A"
med 4-bifenylyl-2-sulfonylklorid
[4-(4-bifenylylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2-naftylsulfonylklorid
[4-(2-naftylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-propylfenylsulfonylklorid
[4-(4-propylfenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2-fenylvinylsulfonylklorid [4-(2-fenylvinylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3-nitro-4-klorfenylsulfonylklorid [4-(3-nitro-4-klorfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2-nitro-4-metoksyfenylsulfonylklorid
[4-(2-nitro-4-metoksyfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med p-tolylsulfonylklorid
[4-(4-tolylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med decylsulfonylklorid
[4-(decylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med benzylsulfonylklorid
[4-(benzylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3-nitro-6-metylbenzylsulfonylklorid
[4-(3-nitro-6-metylbenzylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2,3-diklorfenylsulfonylklorid
[4-(2,3-diklorfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3,4-diklorfenylsulfonylklorid [4-(3,4-diklorfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med fenylsulfonylklorid
[4-(fenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med 3-bromfenylsulfonylklorid [4-(3-bromfenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3,4-dimetoksyfenylsulfonylklorid
[4-(3,4-dimetoksyfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-acetamido-3-klorfenylsulfonylklorid
[4-(4-acetamido-3-klorfenylsulfonyl)piperazin-l-yl]-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-klor-2,5-dimetylfenylsulfonylklorid
[4-(4-klor-2,5-dimetylfenylsulfonyl)piperazin-l-yl]-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med m-tolylsulfonylklorid
4-(3-tolylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med 2-metoksy-5-metylfenylsulfonylklorid
[4-(2-metoksy-5-metylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3-klorfenylsulfonylklorid [4-(3-klorfenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-metoksyfenylsulfonylklorid
[4-(4-metoksyfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2-tienylsulfonylklorid
[4-(2-tienylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-klorfenylsulfonylklorid
[4-(4-klorfenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med isopropylsulfonylklorid
[4-(isopropylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 8-kinolylsulfonylklorid
[4-(8-kinolylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-nitrofenylsulfonylklorid [4-(4-nitrofenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3-klor-6-metoksyfenylsulfonyl [4-(3-klor-6-metoksyfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-acetamidofenylsulfonylklorid
[4-(4-acetamidofenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2, 2, 5, 1,8-pentametylkroman-6-ylsulfonylklorid
[4-(2,2,5,7,8-pentametylkroman-6-ylsulfonyl)piperazin-l-yl ][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med kamfer-10-ylsulfonylklorid
[4-(kamfer-10-ylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 5-(l-metyl-5-trifluormetyl-3-pyrazolyl)-2-tienyl-sulf onylklorid
{4-[5-(l-metyl-5-trifluormetyl-3-pyrazolyl)-2-tienyl-sulf onyl ) piperazin-l-yl }[4-(5-metyl[1,2,4]oksadiazol-3-yl)-fenyl]metanon;
med 2,5-diklorfenylsulfonylklorid
[4-(2,5-diklorfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2,4,6-trimetylfenylsulfonylklorid [4-(2,4,6-trimetylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2-metylsulfonylfenylsulfonylklorid [4-(2-metylsulfonylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 5-benzamidometyl-2-tienyisulfonylklorid
[4-(5-benzamidometyl-2-tienylsulfonyl)piperazin-l-yl ][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med metylsulfonylklorid
[4-(metylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med 1,3-dimetyl-5-klor-4-pyrazolylsulfonylklorid
[4-(1,3-dimetyl-5-klor-4-pyrazolylsulfonyl)piperazin-1-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3,5-dimetyl-4-isoksazolylsulfonylklorid
[4-(3,5-dimetyl-4-isoksazolylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-brom-2-etylfenylsulfonylklorid
[4-(4-brom-2-etylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 1-naftylsulfonynklorid
[4-(1-naftylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 5-dimetylamino-l-naftylsulfonylklorid
[4-(5-dimetylamino-l-naftylsulfonyl)piperazin-l-yl]-[4-(5-metyl[ 1, 2,4]oksadiazol-3-yl)fenyl]metanon;
med 3,4-difluorfenylsulfonylklorid
[4-(3,4-difluorfenylsufonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-tert.-butylfenylsulfonylklorid [4-(4-tert.-butylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-etylfenylsulfonylklorid
[4-(4-etylfenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-(1,1-dimetylpropyl)fenylsulfonylklorid [4-(4-(1,1-dimetylpropyl)fenylsulfonyl)piperazin-l-yl )[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-isopropylfenylsulfonylklorid [4-(4-isopropylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-trifluormetylfenylsulfonylklorid [4-(4-trifluormetylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3-nitro-4-metylfenylsulfonylklorid [4-(3-nitro-4-metylfenylsulfonyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-pentylfenylsulfonylkloride [4-(4-pentylfenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-butylfenylsulfonylklorid
[4-(4-butylfenylsulfonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon; og
med 3-klor-4-metylfenylsulfonylklorid
[4-(3-klor-4-metylfenylsulfonyl)piperazin-l-yl] [4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon.
Eksempel 2
En oppløsning av 100 mg [4-(6-klornaftalen-2-sulfo-nyl)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-metanon i 5 ml metanol blandes med 100 mg Raney-nikkel og en dråpe eddiksyre, og det hydrogeneres fullstendig med atmos-færetrykk og romtemperatur. Katalysator og oppløsningsmiddel fjernes, hvorved man får 4-[4-(6-klornaftalen-2-sulfonyl)-piperazin-l-karbonyl]benzamidinacetat, FAB 457.
Likeledes fås forbindelsene nedenunder fra metanon-derivatene angitt i eksempel 1: 4-[4-(4-bifenylylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 449,
4-[4-(2-naftylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat , EI 405 (M<+>- NH2),
4-[4-(4-propylfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 415,
4-[4-(2-fenylvinylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 39 9,
4-[4-(3-amino-4-klorfenylsulfonyl)piperazin-1-karbonyl]benzamidinacetat, FAB 422,
4-[4-(2-amino-4-metoksyfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 418,
4-[4-(4-tolylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 387,
4-[4-(decylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat , FAB 437,
4-[4-(benzylsulfonyl)piperazin-l-karbonyl]benz-amidineacetat, FAB 387,
4-[4-(3-amino-6-metylbenzylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 402,
4-[4-(2,3-diklorfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 441,
4-[4-(3,4-diklorfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 441,
4-[4-(fenylsulfonyl)piperazin-l-karbonyl]benzamidin-acetat, FAB 37 3,
4-[4-(3-bromfenylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 451, 453,
4-[4-(3,4-dimetoksyfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 433,
4-[4-(4-acetamido-3-klorfenylsulfonyl)piperazin-1-karbonyl]benzamidinacetat, FAB 464,
4-[4-(4-klor-2,5-dimetylfenylsulfonyl)piperazin-1-karbonyl]benzamidinacetat, FAB 435,
4-[4-(3-tolylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 387,
4-[4-(2-metoksy-5-metylfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 417,
4-[4-(3-klorfenylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 407,
4-[4-(4-metoksyfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 402,
4-[4-(2-tienylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat , FAB 379,
4-[4-(4-klorfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 407,
4-[4-(isopropylsulfonyl)piperazin-l-karbonylbenz-amidinacetat , FAB 339,
4-[4-(1,2,3,4-tetrahydrokinolin-8-ylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , FAB 428,
4-[4-(4-aminofenylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat , FAB 388,
4-[4-(3-klor-6-metoksyfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 437,
4-[4-(4-acetamidofenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 437,
4-[4-(2,2,5,7,8-pentametylkroman-6-ylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , FAB 499,
4-[4-(kamfer-10-ylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat , FAB 447,
4-{4-[5-(l-metyl-5-trifluormetyl-3-pyrazolyl)-2-tien-ylsulf onyl ] piperazin-l-karbonyl }benzamidinacetat, FAB 527,
4-[4-(2,5-diklorfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 441,
4-[4-(2,4,6-trimetylfenylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , FAB 415,
4-[4-(2-metylsulfonylfenylsulfonyl)piperazin-l-karbonyl] benzamidinacetat, FAB 451,
4-[4-(5-benzamidometyl-2-tienylsulfonyl)-piperazin-l-karbonyl ]benzamidinacetat , FAB 512,
4-[4-(metylsulfonyl)piperazin-l-karbonyl]benzamidin-acetat, EI 292 (M<+>- NH2),
4-[4-(1,3-dimetyl-5-klor-4-pyrazolylsulfonyl)piper-az in-1-karbonyl]benzamidinacetat,
4-[4-(3,5-dimetyl-4-isoksazolylsulfonyl)piperazin-l-karbony1]benzamidinacetat,
4-[4-(4-brom-2-etylfenylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , EI 461, 463 (M<+>- NH2),
4-[4-(1-naftylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, EI 405 (M<+>- NH2),
4-[4-(5-dimetylamino-l-naftylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, EI 448 (M<+>- NH2),
4-[4-(3,4-difluorfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat,
4-[4-(4-tert.-butylfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 429,
4-[4-(4-etylfenylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 401,
4-[4-(4-(1,1-dimetylpropyl)fenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 442,
4-[4-(4-isopropylfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 415,
4-[4-(4-trifluormetylfenylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , FAB 441,
4-[4-(3-amino-4-metylfenylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , FAB 402,
4-[4-(4-pentylfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 443,
4-[4-(4-butylfenylsulfonyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 42 9, og
4-[4-(3-klor-4-metylfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 421.
Eksempel 3
Ved omsetning med ekvimolare mengder metylklorformiat i pyridin og katalytiske mengder dimetylaminopyridin gir 4-[4-(6-klornaftalen-2-sulfonyl)piperazin-l-karbonyl]benzamidin etter vanlig opparbeidelse forbindelsen metyl{imino-[4-(4-(6-klornaftalen-2-sulfonyl)piperazin-l-karbonyl)fenyl]metyl}-karbamat.
Eksempel 4
På lignende måte som i eksempel 1 gir omsetning av 3-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-l-piperazin-l-ylpropan-l-on [som lar seg erholde fra 3-[4-(5-metyl[1,2,4]oksa-diazol-3-yl)fenyl]-l-(4-tert.-butyloksykarbonyl)piperazin-l-ylpropan-l-on ved behandling med TFA/CH2CI2]og 6-klornafta-len-2-sulfonylklorid forbindelsen l-[4-(6-klornaftalen-2-sulfonyl)piperazin-l-yl]-3-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]propan-l-on, og etter hydrogenering 4-{3-okso-3-[4-(6-klornaftalen-2-sulfonyl)piperazin-l-yl]propyl}benzamidin.
Eksempel 5
På lignende måte som i eksemplene 1 og 2 gir omsetning av [3-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]piperazin-1- ylmetanon og 5-klornaftalen-2-sulfonylklorid etterfulgt av hydrogenering forbindelsen 3-[4-(6-klornaftalen-2-sulfonyl)-piperazin-l-karbonyl]benzamidinacetat, FAB 457.
På lignende måte gir omsetning av [3-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]piperazin-l-ylmetanon med 4-propylfenyl-sulf onylklorid og etterfølgende hydrogenering forbindelsen 3-[4-(4-propylfenylsulfonyl)piperazin-l-karbonylbenzamidin-acetat, FAB 415.
Eksempel 6
På lignende måte som i eksempel 1 gir omsetning av 2- [4-(5-metyl[1,2,4]oksadiazol-3-yl)fenylJ-l-piperazin-l-yl-etan-l-on ("B") og 4-propylfenylsulfonylklorid forbindelsen 1-[4-(4-propylfenylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on og etter hydrogenering 4-{2-okso-2-[4-(4-propylfenylsulfonyl)piperazin-l-yl]etyl}-benzamidin, FAB 429.
På lignende måte gir omsetning av "B"
med decylsulfonylklorid
l-[4-(decylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med fenylsulfonylklorid l-[4-(fenylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med 3,4-diklorfenylsulfonylklorid
1-[4-(3,4-diklorfenylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med benzylsulfonylklorid
1-[4-(benzylsulfonyl)piperazin-l-yl]-2-[4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med 3,4-dimetoksyfenylsulfonylklorid
1-[4-(3,4-dimetoksyfenylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med isopropylsulfonylklorid
l-[4-(isopropylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med kamfer-10-ylsulfonylklorid l-[4-(kamfer-10-ylsulfonyl)piperazin-l-yl]-2-[4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med 3-metoksy-4-metoksykarbonyl-2-tienylsulfonylklorid
1-[4-(3-metoksy-4-metoksykarbonyl-2-tienylsulfonyl)-piperazin-l-yl]-2-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-etan-l-on;
med 2,4,6-trimetylfenylsulfonylklorid l-[ 4-(-2, 4, 6-trimetylf enyl suf onyl) piperazin-l-yl ] -2-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med 2-fenylvinylsulfonylklorid 1-[4-(2-fenylvinylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med metylsulfonylklorid l-[4-(metylsulfonyl)piperazin-l-yl]-2-[4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med [2,1,3]benzotiadiazol-4-ylsulfonylklorid
1-[4-([2,1,3]benzotiadiazol-4-ylsulfonyl)-piperazin-l-yl ]-2-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on; med 2,4-diklorfenylsulfonylklorid l-[4-(2,4-diklorfenylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med 1-naftylsulfonylklorid
1-[4-(1-naftylsulfonyl)piperazin-l-yl]-2-[4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med 2-naftylsulfonylklorid
1-[4-(2-naftylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]etan-l-on;
med 5-dimetylamino-1-naftylsulfonylklorid l-[4-(5-dimetylamino-l-naftylsulfonyl)piperazin-l-yl ] -2- [ 4- ( 5-metyl [1,2,4]oksadiazol-3-yl)fenyl]etan-l-on; og med 4-metylsulfonylfenylsulfonylklorid 1-[4-(4-metylsulfonylfenylsulfonyl)piperazin-l-yl]-2-[4-(5-metyl[1,2,4)oksadiazol-3-yl)fenyl]etan-l-on.
Ved hydrogenering gir disse forbindelsene amidinderivatene nedenunder: 4-{2-okso-2-[4-(decylsulfonyl)piperazin-l-yl]etyl}-benzamidinacetat, FAB 450,
4-{ 2-okso-2-[4-(fenylsulfonyl)piperazin-l-yl]etyl}-benzamidinacetat, FAB 387,
4-{2-okso-2-[4-(3,4-diklorfenylsulfonyl)piperazin-l-yl]etyl}benzamidinacetat, FAB 454,
4-{2-okso-2-[4-(benzylsulfonyl)piperazin-l-yl]etyl}-benzamidinacetat, FAB 401,
4-{2-okso-2-[4-(3,4-dimetoksyfenylsulfonyl)piperazin-l-yl ] etyl }benzamidinacetat , FAB 447,
4-{2-okso-2-[4-(isopropylsulfonyl)piperazin-l-yl]-etyl}benzamidinacetat, FAB 353,
4-{2-okso-2-[4-(kamfer-10-ylsulfonyl)piperazin-l-yl]-etyl}benzamidinacetat, FAB 353,
4-{2-okso-2-[4-(3-metoksy-4-metoksykarbonyl-2-tienyl-sulfonyl)piperazin-l-yl]etyl}benzamidinacetat, FAB 481,
4-{2-okso-2-[4-(2,4,6-trimetylfenylsulfonyl)piperazin-l-yl ]etyl}benzamidinacetat, FAB 429,
4-{2-okso-2-[4-(2-fenylvinylsulfonyl)piperazin-l-yl]-etyl}benzamidinacetat, FAB 413,
4-{2-okso-2-[4-(metylsulfonyl)piperazin-l-yl]etyl}-benzamidinacetat, FAB 325,
4-{2-okso-2-[4-(2,3-diaminofenylsulfonyl)piperazin-l-yl ]etylJbenzamidinacetat, FAB 415,
4-{2-okso-2-[4-(2,4-diklorfenylsulfonyl)piperazin-l-yl]etyl}benzamidinacetat, FAB 455,
4-{2-okso-2-[4-(1-naftylsulfonyl)piperazin-l-yl]-etyl}benzamidinacetat, FAB 437,
4-{2-okso-2-[4-(2-naftylsulfonvl)piperazin-l-yl]-etyl}benzamidinacetat, FAB 437,
4-{2-okso-2-[4-(5-dimetylamino-1-naftylsulfonyl)-piperazin-l-yl]etyl}benzamidinacetat, FAB 480, og
4-{ 2-okso-2-[4-(4-metylsulfonylfenylsulfonyl)piperazin-l-yl]etyl}benzamidinacetat, FAB 465.
Eksempel 7
På lignende måte som i eksempel 1 gir omsetning av
"A"
med 4-bifenylylkarbonylklorid
[4-(4-fenylbenzoyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med syklopentylkarbonylklorid
[4-(syklopentylkarbonyl)piperazin-l-yl][4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med fenoksyacetylklorid
[4-(fenoksyacetyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med 1-naftylkarbonylklorid [4-(1-naftylkarbonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2-naftylkarbonylklorid [4-(2-naftylkarbonyl)piperazin-l-yl][4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med nikotinoylklorid
[4-(nikotinoyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med 3-nitrobenzoylklorid
[4-(3-nitrobenzoyl)piperazin-l-yl][4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]metanon;
med benzo-[b]tiofen-2-karbonylklorid
[4-(benzo-[b]tiofen-2-karbonyl)piperazin-l-yl][4-(5-metylf1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-trifluormetoksybenzoylklorid
[4-(4-trifluormetoksybenzoy1)piperazin-l-yl][4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 2,5-dimetoksyfenylacetylklorid
[4-(2,5-dimetoksyfenylacetyl)piperazin-l-yl] [4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 4-klorfenylacetylklorid
[4-(4-klorfenylacetyl)piperazin-l-yl][4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 1,3-benzodioksol-5-karbonylklorid
[4-(1,3-benzodioksol-5-karbonyl)piperazin-l-yl][4-(5-mety1[1,2,4]oksadiazol-3-yl)fenyl]metanon;
med 3,4-diklorbenzoylklorid
[ 4-(3,4-diklorbenzoyl)piperazin-l-yl][4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]metanon; og
med isobutylklorformiat
[4-(isobutyloksykarbonyl)piperazin-l-yl][4-(5-mety1-[1,2,4]oksadiazol-3-yl)fenyl]metanon.
Ved hydrogenering gir disse forbindelsene amidinderivatene nedenunder: 4-[4-(4-fenylbenzoyl)piperazin-l-karbonyl]benzamidin-acetat, FAB 413,
4-[4-(syklopentylkarbonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 329,
4-[4-(fenoksyacetyl)piperazin-l-karbonyl]benzamidin-acetat, FAB 367,
4-[4-(1-naftylkarbonyl)piperazin-l-karbonylbenz-amidinacetat, FAB 387,
4-[4-(2-naftylkarbonyl)piperazin-l-karbonylbenz-amidinacetat, FAB 387,
4-[4-(nikotinoyl)piperazin-l-karbonylbenzamidin-acetat, FAB 338,
4-[4-(3-aminobenzoyl)piperazin-l-karbonyl]benzamidin, 4-[4-(benzo-[bltiofen-2-karbonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 393,
4-[4-(4-trifluormetoksybenzoy1)piperazin-l-karbonyl]-benzamidinacetat, FAB 421,
4-[4-(2,5-dimetoksyfenylacetyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 411,
4-[4-(4-klorfenylacetyl)piperazin-l-karbonyl]benz-amidinacetat , FAB 385,
4-[4-(1,3-benzodioksol-5-karbonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 381,
4-[4-(3,4-diklorbenzoyl)piperazin-l-karbonyl]benz-amidinacetat , FAB 381, og
4-[4-(isobutyloksykarbonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 333.
Eksempel 8
Omsetning av ekvimolare mengder acetylklorid i pyridin og katalytiske mengder dimetylaminopyridin gir etter vanlig opparbeidelse
med 4-[4-(6-klornaftalen-2-sulfonyl)piperazin-l-karbonyl]benzamidin
N-{imino-4-[4-(6-klornaftalen-2-sulfonyl)piperazin-l-karbonyl ]fenylmetyl}acetamid.
Eksempel 9
Omsetning av ekvimolare mengder 4-cyanbenzylbromid, BOC-piperazin og trietylamin i diklormetan gir l-(4-cyan-benzyl)-4-(tert.-butyloksykarbonyl)piperazin.
Omsetning med a) hydroksylaminhydroklorid, trietylamin i etanol og b) eddiksyreanhydrid gir l-[4-(5-mety1-[1,2,4]oksadiazol-3-yl)benzyl]-4-(tert.-butyloksykarbonyl)-piperazin.
På lignende måte som i eksemplene 1 og 2 gir, etter fjerning av BOC-gruppen med TFA i CH2Cl2, omsetning av l-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]piperazin med 6-klor-nåftalen-2-sulfonylklorid, etterfølgende hydrogenering og vanlig opparbeidelse forbindelsen 4-[(6-klornaftalen-2-sulfo-nyl)piperazin-l-ylmetyl]benzamidin.
Forbindelsene nedenunder fås på lignende måte: 4-[(4-bifenylylsulfonyl)piperazin-l-ylmetyl]benz-amidin,
4-[(2-naftylsulfonyl)piperazin-l-ylmetyl]benzamidin,
4-[(4-propylfenylsulfonyl)piperazin-l-ylmetylbenz-amidin og
4-[(2-fenylvinylsulfonyl)piperazin-l-yl-metyl]benz-amidin.
Eksempel 10
Omsetning av ekvimolare mengder 4-(5-metyl[l,2,4]-oksadiazol-3-yl]benzosyre, difenylfosforylazid og trietylamin i DMF gir etter vanlig opparbeidelse 4-(5-metyl[1,2,4]oksa-diazol-3-yl)benzoylazid.
Oppvarming med BOC-piperazin i toluen gir i en om-ordningsreaksjon etter vanlig opparbeidelse l-BOC-4-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenylkarbamoyl]piperazin. Fjerning av BOC-gruppen med TFA i CH2C12gir 4-[4-(5-metyl[1,2,4]oksa-diazol-3-yl)fenylkarbamoyl]piperazin ("C").
På lignende måte som i eksemplene 1 og 2 gir omsetning av "C" med 6-klornaftalensulfonylklorid og etterfølgende hydrogenering forbindelsen N-(4-amidinofenyl)-4-(6-klornafta-len-2-sulfonyl)piperazin-l-karboksamid.
Forbindelsene nedenunder fås på lignende måte: N-(4-amidinofenyl)-4-(4-bifenylylsulfonyl)piperazin-1-karboksamid,
N-(4-amidinofenyl)-4-(2-naftylsulfonyl)piperazin-l-karboksamid,
N-(4-amidinofenyl)-4-(4-propylfenylsulfonyl)piperazin-l-karboksamid og
N-(4-amidinofeny1)-4-(2-fenylvinylsulfonyl)piperazin-1-karboksamid.
Eksempel 11
Omsetning av ekvimolare mengder l-BOC-4-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenylkarbamoyl]piperazin, metylbrom-acetat og kalium-tert.-butoksid i DMF gir etter vanlig opparbeidelse forbindelsen metyl-{(4-BOC-piperazin-l-karbonyl)[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]amino}acetat.
Omsetning med a) HCl/dioksan. og b) NaOH gir forbindelsen metyl{(piperazin-l-karbonyl)[4-(5-metyl[l,2,4]oksa-diazol-3-yl)fenyl]amino}acetat.
Omsetning med 6-klornaftalensulfonylklorid gir på lignende måte som i eksempel 1 forbindelsen metyl-{[4-(6-klor-naf talen-2-sulfonyl)piperazin-l-karbonyl]{4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]amino}acetat.
Dette gir ved hydrogenering over Raney-nikkel metyl-
{[4-(6-klornaftalen-2-sulfonyl)piperazin-l-karbonyl][4-ami-dinof enyl ] amino} acetat .
Metylesteren spaltes ved behandling med NaOH i metanol/vann. Vanlig opparbeidelse gir {[4-(6-klornaftalen-2-sulfonyl)piperazin-l-karbonyl][4-amidinofenyl]amino}eddiksyre. På lignende måte fås forbindelsene nedenunder: {[4-(4-bifenylylsulfonyl)piperazin-l-karbonyl]-[4-amidinofeny1]amino}eddiksyre,
{[4-(2-naftylsulfonyl)piperazin-l-karbonyl][4-ami-dinof enyl ]amino}eddiksyre,
{[ 4- (4-propylf enylsulf onyl) piperazin-1- karbonyl ] [ 4-amidinofenyl]amino}eddiksyre og
{[4-(2-fenylvinylsulfonyl)piperazin-l-karbonyl][4-amidinofeny1]amino}eddiksyre.
Eksempel 12
Omsetning av ekvimolare mengder 4-(5-metyl[l,2,4]-oksadiazol-3-yl)fenyleddiksyre, metyljodid og kaliumkarbonat gir metyl-4-(5-metyl[l,2,4]oksadiazol-3-yl)fenylacetat ("D").
Oppvarming av ekvimolare mengder av BOC-piperazin og kloracetylklorid i toluen gir etter vanlig opparbeidelse 1-BOC-4-klormetylkarbonylpiperazin ("E").
Omsetning av "D" og "E" med NaH i DMF gir etter vanlig opparbeidelse forbindelsem metyl-4-(4-BOC-piperazin-l-yl)-2-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]-4-oksobutyrat.
Omsetning med a) HCl/dioksan og b) NaOH gir forbindelsen metyl-4-(piperazin-l-yl)-2-[4-(5-metyl[1,2,4]oksa-diazol-3-yl)fenyl]-4-oksobutyrat.
Omsetning med 6-klornaftalensulfonylklorid gir, på lignende måte som i eksempel 1, forbindelsen metyl-4-[4-(6-klornaftalen-2-sulfonyl)piperazin-l-yl]-2-[4-(5-metyl[1,2,4]-oksadiazol-3-yl)fenyl]-4-oksobutyrat.
Dette gir ved hydrogenering på lignende måte som i eksempel 2 forbindelsen metyl-4-[4-(6-klornaftalen-2-sulfo-nyl)piperazin-l-yl]-2-[4-amidinofeny1]-4-oksobutyrat.
Metylesteren spaltes ved behandling med NaOH i metanol/vann. Vanlig opparbeidelse gir 4-[4-(6-klornaftalen-2-sulfonyl)piperazin-l-yl]-2-(4-amidinofenyl)-4-oksosmørsyre. Forbindelsene nedenunder fås på en lignende måte: 4-[4-(4-bifenylylsulfonyl)piperazin-l-yl]-2-(4-amidinofenyl)-4-oksosmørsyre,
4-[4-(2-naftylsulfonyl)piperazin-l-yl]-2-(4-amidino-fenyl)-4-oksosmørsyre,
4-[4-(4-propylfenylsulfonyl)piperazin-l-yl]-2-(4-amidinofenyl)-4-oksosmørsyre,
4-[4-(2-fenylvinylsulfonyl)piperazin-l-yl]-2-(4-amidinofenyl)-4-oksosmørsyre.
Eksempel 13
Omsetning av ekvimolare mengder av "A" og fenyl-isocyanat i diklormetan ved romtemperatur gir etter vanlig opparbeidelse forbindelsen N-fenyl-4-[4-(5-metyl[l,2,4]oksa-diazol-3-yl)benzoyl]piperazin-l-karboksamid.
På lignende måte gir omsetning av "A":
med 4-trifluormetylfenylisocyanat
N-(4-trifluormetylfenyl)-4-[4-(5-metyl[1,2,4]oksa-diazol-3-yl)benzoyl]piperazin-l-karboksamid;
med butylisocyanat
N-butyl-4-[4-(5-metyl[1,2,4]oksadiazol-3-y1)benzoyl]-piperazin-l-karboksamid;
med 1-naftylisocyanat
N-(1-nafty1)-4-[4-(5-metyl[1,2,4]oksadiazol-3-yl)-benzoyl]piperazin-l-karboksamid;
med 4-metoksyfenylisocyanat
N-(4-metoksyfenyl)-4-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzoyl]piperazin-l-karboksamid;
med 4-nitrofenylisocyanat
N-(4-nitrofenyl)-4-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzoyl]piperazin-l-karboksamid;
med sykloheksylisocyanat
N-sykloheksyl-4-[4-(5-metyl[1,2,4]oksadiazol-3-yl)-benzoyl]piperazin-l-karboksamid;
med 3-etoksykarbonylfenylisocyanat
N-(3-etoksykarbonylfenyl)-4-[4-(5-metyl[1,2,4]-oksadiazol-3-yl)benzoyl]piperazin-l-karboksamid.
Disse forbindelsene gir ved hydrogenering på lignende måte som i eksempel 2 amidinderivatene nedenunder: N-fenyl-4-(4-amidinobenzoyl)piperazin-l-karboksamid-acetat, FAB 352,
N-butyl-4-(4-amidinobenzoyl)piperazin-l-karboksamid-acetat, FAB 332,
N-(1-naftyl)-4-(4-amidinobenzoyl)piperazin-l-karboks-amidacetat, FAB 402,
N-(4-metoksyfenyl)-4-(4-amidinobenzoyl)piperazin-l-karboksamidacetat, FAB 382,
N-(4-aminofenyl)-4-(4-amidinobenzoyl)piperazin-l-karboksamidacetat, FAB 3 67,
- N-sykloheksyl-4-(4-amidinobenzoyl)piperazin-l-karboksamidacetat, FAB 358, og
N-(3-etoksykarbonylfeny1)-4-(4-amidinobenzoyl)piperazin-l-karboksamidacetat, FAB 424.
Eksempel 14
På lignende måte som i eksemplene 1 og 2 fås forbindelsene nedenunder: 3-[4-(2-naftylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 423,
3-[4-(3-klor-4-metylfenylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat, FAB 421,
3-[4-(2,4,6-triklorfenylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , FAB 475,47 7,
3-[4-(3-amino-4-klorfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 422,
3-[4-(4-klorfenylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 407,
3-[4-(3-trifluormetylfenylsulfonyl)piperazin-l-karbonyl ]benzamidinacetat, FAB 441,
3- [4-(4-bifenylylsulfonyl)piperazin-l-karbonyl]benz-amidinacetat, FAB 449,
4- [4-(3,5-dimetoksyfenylsulfonyl)piperazin-l-karbonyl]benzamidinacetat, FAB 433,
4-[4-(dibenzofuran-2-ylsulfonyl)piperazin-l-karbonyl] benzamidinacetat, FAB 463,
4-[4-(3-fluor-4-metoksyfenylsulfonyl)piperazin-l-karbonyl ]benzamidinacetat, FAB 421,
4-[4-(2,4-diklor-6-metoksyfenylsulfonyl)piperazin-l-karbonyl ] benzamidinacetat , FAB 471,
4-(4-benzylpiperazin-l-karbonyl)benzamidinacetat, FAB 323,
4-[4-(2-naftylmetyl)piperazin-l-karbonyl]benzamidin-acetat, FAB 37 3,
4-[4-(4-metoksyfenylmetyl)piperazin-l-karbonyl]benz-amidindiacetat, FAB 353,
4-[4-(4-metoksykarbonylfenylsulfonyl)piperazin-l-karbonyl] benzamidinacetat, FAB 431,
4-[4-(4-propylfenylsulfonyl)piperazin-l-karbonyl]-3-metylbenzamidinacetat, FAB 429,
4-[4-(2-naftylsulfonyl)piperazin-l-karbonyl]-3-metyl-benzamidinacetat, FAB 437,
4-[4-(6-klor-2-naftylsulfonyl)piperazin-l-karbonyl]-3-metylbenzamidinacetat, FAB 471,
4-[4-(7-metoksy-2-naftylsulfonyl)piperazin-l-karbo-nylbenzamidinacetat, FAB 453, og
4-[4-(3,5-dimetoksyfenylmetyl)piperazin-l-karbonyl]-benzamidinacetat, FAB 383.
Eksempel 15
På lignende måte som i eksempel 6 fås forbindelsene nedenunder: 4-{3-okso-3-[4-(butylsulfonyl)piperazin-l-yl]propyl}-benzamidacetat, FAB 381,
4-(3-okso-3-[4-(4-propylfenylsulfonyl)piperazin-l-yl ]propyl }benzamidinacetat, FAB 443,
4-{3-okso-3-[4-(6-klor-2-naftylsulfonyl)piperazin-l-yl ]propyl }benzamidinacetat, FAB 485,
4-{3-okso-3-[4-(2-naftylsulfonyl)piperazin-l-yl]-propyl}benzamidinacetat, FAB 451,
4-{3-okso-3-[4-(3-klor-4-metylfenylsulfonyl)piperazin-l-yl]propyl}benzamidinacetat, FAB 449,
4-{3-okso-3-[4-(4-klorfenylsulfonyl)piperazin-l-yl]-propyl}benzamidinacetat, FAB 435,
4-{3-okso-3-[4-(4-bifenylylsulfonyl)piperazin-l-yl]-propyl}benzamidinacetat, FAB 47 7,
4-{3-okso-3-[4-(2-4,6-trimetylfenylsulfonyl)piperazin-l-yl]propyl)benzamidinacetat, FAB 443,
3-{3-okso-3-[4-(butylsulfonyl)piperazin-l-yl]propyl}-benzamidinacetat, FAB 381,
3-{3-okso-3-[4-(4-metoksyfenylsulfonyl)piperazin-l-yl ] propyl ) benzamidinacetat, FAB 431,
3-{3-okso-3-[4-(4-klorfenylsulfonyl)piperazin-l-yl]-propyl}benzamidinacetat, FAB 435,
3-{3-okso-3-[4-(4-isopropylfenylsulfonyl)piperazin-l-yl]propyl}benzamidinacetat, FAB 443,
3-{3-okso-3-[4-(2,4,6-trimetylfenylsulfonyl)piperazin-l-yl]propyl}benzamidinacetat, FAB 443,
3-{3-okso-3-[4-(3-klor-4-metylfenylsulfonyl)piperazin-l-yl ]propyl }benzamidinacetat, FAB 449,
3-{3-okso-3-[4-(6-klor-2-naftylsulfonyl)piperazin-l-yl]propyl}benzamidinacetat, FAB 485,
3-{3-okso-3-[4-(2-naftylsulfonyl)piperazin-l-yl]-propyl}benzamidinacetat, FAB 451, og
3-{3-okso-3-[4-(4-bifenylylsulfonyl)piperazin-l-yl]-propyl}benzamidinacetat, FAB 47 7.
Eksempel 16
På lignende måte som i eksempel 13 gir omsetning av 4-(5-metyl[1,2,4]oksadiazol-3-yl)fenylisocyanat ("F")
med l-(2-naftylsulfonyl)piperazin
N-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(2-naftylsulfonyl)piperazin-l-karboksamid med l-(2-fenylvinylsulfonyl)piperazin
N-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(2-fenylvinylsulfonyl)piperazin-l-karboksamid;
med l-(4-propylfenylsulfonyl)piperazin
N-[4-(5-metyl[l,2,4]oksadiazol-3-yl)fenyl]-4-(4-propylfenylsulfonyl)piperazin-l-karboksamid;
med l-(4-klorfenylsulfonyl)piperazin
N-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(4-klor-fenylsulfonyl)piperazin-l-karboksamid;
med l-(2,4,6-trimetylfenylsulfonyl)piperazin
N-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(2,4,6-trimetylfenylsulfonyl)piperazin-l-karboksamid; og
med l-(6-klor-2-naftylsulfonyl)piperazin
N-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(6-klor-2-naftylsulfonyl)piperazin-l-karboksamid.
Ved hydrogenering på lignende måte som i eksempel 2 gir disse amidinderivatene nedenunder: N-(4-amidinofenyl)-4-(2-naftylsulfonyl)piperazin-l-karboksamidacetat, FAB 438,
N-(4-amidinofenyl)-4-(2-fenylvinylsulfonyl)piperazin-1-karboksamidacetat, FAB 414,
N-(4-amidinofenyl)-4-(4-propylfenylsulfonyl)piperazin-l-karboksamidacetat, FAB 430,
N-(4-amidinofenyl)-4-(4-klorfenylsulfonyl)piperazin-l-karboksamid; acetat, FAB 422,
N-(4-amidinofenyl)-4-(2,4,6-trimetylfenylsulfonyl)-piperazin-l-karboksamidacetat, FAB 430, og
N-(4-amidinofenyl)-4-(6-klor-2-naftylsulfonyl)piperazin-l-karboksamidacetat , FAB 472.
Eksempel 17
På lignende måte som i eksempel 1 gir omsetning av 1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]piperazin ("G")
med 4-propylfenylsulfonylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(4-propylfenylsulfonyl)piperazin;
med 4-metoksyfenylsulfonylklorid
l-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(4-metoksyfenylsulfonyl)piperazin;
med 4-bifenylylsulfonylklorid l-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(4-bifenylylsulfonyl)piperazin;
med 2-naftylsulfonylklorid 1-[4-(5-metyl[l,2,4]oksadiazol-3-yl)benzyl]-4-(2-naftylsulfonyl)piperazin;
med 6-klor-2-naftylsulfonylklorid 1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl)-4-(6-klor-2-naftylsulfonyl)piperazin,■
med 7-metoksy-2-naftylsulfonylklorid 1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(7-metoksy-2-naftylsulfonyl)piperazin;
med 3,5-dimetoksybenzylklorid l-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(3,5-dimetoksybenzy1)piperazin;
med 4-isopropylfenylsulfonylklorid l-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)benzyl]-4-iso-propylf enylsulfonyl)piperazin;
med 4-bifenylylkarbonylklorid l-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(4-bifenylylkarbonyl)piperazin;
med 2-naftylkarbonylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(2-naftylkarbonyl)piperazin;
med 3,5-dimetoksybenzylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(3,5-dimetoksybenzyl)piperazin; og
med 2-naftylmetylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)benzyl]-4-(2-naftylmetyl)piperazin.
Ved hydrogenering på lignende måte som i eksempel 2 gir disse amidinderivatene nedenunder: 1-(4-amidinobenzyl)-4-(4-propylfenylsulfonyl)piper-azinacetat, FAB 401, l-(4-amidinobenzyl)-4-(4-metoksyfenylsulfonyl)piper-azinacetat, FAB 389,
1-(4-amidinobenzyl)-4-(4-bifenylylsulfonyl)piperazin-acetat, FAB 435,
1-(4-amidinobenzyl)-4-(2-naftylsulfonyl)piperazin-acetat, FAB 409, l-(4-amidinobenzyl)-4-(6-klor-2-naftylsulfonyl)piperazin acetat, FAB 443, l-(4-amidinobenzyl)-4-(7-metoksy-2-naftylsulfonyl)-piperazinacetat, FAB 439,
1-(4-amidinobenzyl)-4-(3,5-dimetoksybenzyl)piperazin-acetat, FAB 369, l-(4-amidinobenzyl)-4-(4-isopropylfenylsulfonyl)-piperazinacetat, FAB 441,
1-(4-amidinobenzyl)-4-(4-bifenylylkarbonyl)piperazin-diacetat, FAB 399,
1-(4-amidinobenzyl)-4-(2-naftylkarbonyl)piperazin-diacetat, FAB 37 3,
l-(4-amidinobenzyl)-4-(3,5-dimetoksybenzyl)piperazin-diacetat, FAB 3 69, og
1-(4-amidinobenzyl)-4-(2-natylmetyl)piperazindiace-tat, FAB 359.
Eksempel 18
Ved omsetning av 4-[4-(6-klor-2-naftylsulfonyl)-piperazin-l-karbonyl]-3-metylbenzamidin med metylklorformiat i diklormetan fås forbindelsen metyl(imino-{4-[4-(6-klor-2-naftylsulfonyl)piperazin-l-karbonyl]fenyl}metyl)karbamat etter vanlig opparbeidelse
Eksempel 19
På lignende måte som i eksempel 1 gir omsetning av 1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]piperazin ("H")
med 4-propylfenylsulfonylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(4-propylfenylsulfonyl)piperazin;
med 4-butylsulfonylklorid
l-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(4-butylsulfonyl)piperazin;
med 4-metoksyfenylsulfonylklorid l-[4-(5-metyl[l,2,4]oksadiazol-3-yl)fenyl]-4-(4-metoksyfenylsulfonyl)piperazin;
med 4-klorfenylsulfonylklorid 1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(4-klor-fenylsulfonyl)piperazin;
med 4-isopropylfenylsulfonylklorid 1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(4-iso-propylf enylsulf onyl ) piperazin;
med 4-bifenylylsulfonylklorid l-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(4-bifenylylfenylsulfonyl)piperazin;
med 2,4,6-trimetylfenylsulfonylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(2,4,6-trimetylfenylsulfonyl)piperazin;
med 3-klor-4-metylfenylsufonylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(3-klor-4-metylfenylsulfonyl)piperazin;
med 2-naftylsulfonylklorid
l-[4-(5-metyl-[1,2,4]oksadiazol-3-yl)fenyl]-4-(2-naftylsulfonyl)piperazin; og
med 6-klor-2-naftylsulfonylklorid
1-[4-(5-metyl[1,2,4]oksadiazol-3-yl)fenyl]-4-(6-klor-2-naftylsulfonyl)piperazin.
Ved hydrogenering på lignende måte som i eksempel 2 gir disse amidinderivatene nedenunder: (1-(4-amidinofeny1)-4-(4-propylfenylsulfonyl)piper-azinacetat, FAB 387, l-(4-amidinofenyl)-4-(4-butylsulfonyl)piperazin-acetat, FAB 325, 1-(4-amidinofenyl)-4-(4-metoksyfenylsulfonyl)piper-azinacetat, FAB 375, l-(4-amidinofenyl)-4-(4-klorfenylsulfonyl)piperazin-acetat, FAB 37 9,
1-(4-amidinofenyl)-4-(4-isopropylfenylsulfonyl)piper-azinacetat, FAB 387,
1-(4-amidinofeny1)-4-(4-bifenylylfenylsulfonyl)piper-azinacetat, FAB 421,
1-(4-amidinofenyl)-4-(2,4,6-trimetylfenylsulfonyl)-piperazinacetat, FAB 387,
1-(4-amidinofenyl)-4-(3-klor-4-metylfenylsulfonyl)-piperazinacetat, FAB 393,
1-(4-amidinofenyl)-4-(2-naftylsulfonyl)piperazin-acetat, FAB 395, og l-(4-amidinofenyl)-4-(6-klor-2-naftylsulfonyl)piper-azinacetat, FAB 429.
De etterfølgende eksempler vedrører farmasøytiske preparater.
Eksempel A
Inieksionsampuller
En oppløsning av 100 g av en aktiv forbindelse med formel I og 5 g dinatriumhydrogenfosfat i 3 1 dobbeltdestillert vann bringes til pH 6,5 med 2 N saltsyre og underkastes sterilfiltrering, og injeksjonsampuller fylles med oppløs-ningen, lyofiliseres under sterile betingelser og lukkes under sterile betingelser. Hver injeksjonsampulle inneholder 5 mg aktiv forbindelse.
Eksempel B
Suppositorier
En blanding av 2 0 g av en aktiv forbindelse med formel I med 100 g soyalecitin og 1400 g kakaosmør smeltes, helles i former og får avkjøles. Hvert suppositorium inneholder 20 mg aktiv forbindelse.
Eksempel C
Oppløsning
En oppløsning fremstilles fra 1 g av en aktiv forbindelse med formel I, 9,38 g NaH2P04- 2 H20, 28,48 g Na2-HP0412 H20 og 0,1 g benzalkoniumklorid i 940 ml dobbeltdestillert vann. Den bringes til pH 6,8, fylles opp til 1 1 og steriliseres ved bestråling. Denne oppløsningen kan anvendes i form av øyedråper.
Eksempel D
Salve
500 g av en aktiv forbindelse med formel I blandes med 99,5 g vaselin under aseptiske betingelser.
Eksempel E
Tabletter
En blanding av 1 kg aktiv forbindelse med formel I,
4 kg laktose, 1,2 kg potetstivelse, 0,2 kg talkum og 0,1 kg magnesiumstearat presses til tabletter på vanlig måte, slik at hver tablett inneholder 10 mg aktiv forbindelse.
Eksempel F
Belagte tabletter
Tabletter presses analogt med eksempel E og belegges så på vanlig måte med et belegg av sukrose, potetstivelse, talkum, tragantgummi og fargestoff.
Eksempel G
Kapsler
Harde gelatinkapsler fylles med 2 kg aktiv forbindelse med formel I på vanlig måte i, slik at hver kapsel inneholder 20 mg av den aktive forbindelse.
Eksempel H
Ampuller
En oppløsning av 1 kg aktiv forbindelse med formel I i 60 1 dobbeltdestillert vann underkastes sterilfiltrering, og ampuller fylles med oppløsningen, lyofiliseres under sterile betingelser og lukkes under sterile betingelser. Hver ampulle inneholder 10 mg aktiv forbindelse.
Claims (9)
1. Forbindelse,
karakterisert ved at den har formel I
hvor
R<1> er -C(=NH)-NH2 , som også kan være monosubstituert med-COA, -CO-[C(R <6> )2]n -Ar, -COOA, -0H eller med en vanlig aminobeskyttelsesgruppe,
R<2> er H, A, OR <6> , N(R <6> )2 , N02 , CN, Hal, NHCOA, NHCOAr,
NHS02 A, NHSO 2Ar, COOR 6, CON(R <6> )2 , CONHAr, COR <6> , COAr, S(0)n A eller S(0)n Ar,
R<3> er A, sykloalkyl, -[C(R6 ) 2 ] n-Ar, -[C(R6)2 ]n-0 Ar,
~[C(R6) 2]n-Het eller -C(R6) 2=C(R6)2-Ar ,
R<6> er H, A eller benzyl,
X er fraværende, -CO-, -C(R <6> )2"/ -C(R <6> )2 -C (R <6> )2 -,
-C(R <6> )2 -CO-, -C(R <6> )2 -C(R <6> )2 -CO-, -C(R <6> )2 =-C(R <6> )-CO-, -NR <6> CO-, -N{ [C(R6)2]n-COOR6}-CO- eller -C-(COOR <6> )R <6-> C(R <6> )2 -C0-,
Y er -C(R <6> )2 -, -S02 -, -CO-, -C00- eller -CONR <6-> ,
A er alkyl med 1-20 C-atomer, hvor én eller to CH2 -
grupper kan være erstattet med 0- eller S-atomer, eller med -CR<6> =CR<6> -grupper, og/eller 1-7 H-atomer kan være erstattet med F,
Ar er naftyl eller fenyl som er usubstituert eller
mono-, di- eller trisubstituert med A, Ar', OR <6> , N(R <6> )2 , N02 , CN, Hal, NHCOA, NHCOAr', NHS02 A,
NHS02 Ar', COOR 6, CON(R <6> )2 , CONHAr', COR <6> , COAr', S(0)n A eller S(0)n Ar,
Ar' er naftyl eller fenyl som er usubstituert eller
mono-, di- eller trisubstituert med A, OR <6> ,N (R 6)2 , N02, CN, Hal, NHCOA, COOR <6> , CON(R<6> )2 , COR <6> eller S(0)n A,
Het er et mono- eller bisyklisk, mettet eller umettet
heterosyklisk ringsystem som inneholder ett, to, tre eller fire identiske eller forskjellige heteroatomer, slik som nitrogen, oksygen og svovel, og som er usubstituert eller mono- eller polysubstituert med Hal, A, Ar', COOR <6> , CN, N(R <6> )2 , N02 , Ar-CONH-CH2 og/eller kabonyloksygen,
Hal er F, Cl, Br eller I, og
n er 0, 1 eller 2,
og salter derav.
2. Forbindelse ifølge krav 1, karakterisert ved at den er:
a) 4-[4-(4-propylfenylsulfonyl)-1-piperazinylkarbonyl]-benzamidin,
b) 4-[4-(3-amino-4-klorfenylsulfonyl)-1-piperazinyl-karbonyl ] benzamidin,
c) 4-[4-(6-klornaftalen-2-sulfonyl)-1-piperazinylkarbo-nyl ] benzamidin eller
d) 4-[4-(2-fenylvinylsulfonyl)-1-piperazinylkarbonyl]-
benzamidin,
og salter derav.
3. Fremgangsmåte for fremstilling av forbindelser med formel I ifølge krav 1 og salter derav, karakterisert ved at
a) de frigjøres fra et av sine funksjonelle derivater ved behandling med et solvolyserings- eller hydrogenolyseringsmiddel, ved
i) frigjøring av en amidinogruppe fra dens oksadiazolderivat ved hydrogenolyse,
ii) erstatning av en vanlig aminobeskyttelsesgruppe
ved behandling med et solvolyserings- eller hydrogenolyseringsmiddel med hydrogen, eller frigjøring av en aminogruppe som er beskyttet ved hjelp av en vanlig beskyttelsesgruppe, eller
b) for fremstilling av forbindelser med formel I hvorR<1>
er
X er -CO- eller -C(R <6> )2 -CO-,
og R <2> ,R<3> og Y er som definert i krav 1, en forbindelse med formel II
hvor R <3> og Y er som definert i krav 1, omsettes med en forbindelse med formel III
hvor R <1> er
X er -CO- eller -C(R <6> )2 -CO-,
R<2> er som definert i krav 1,
og L er Cl, Br, I eller en fri eller reaktiv, funksjonelt derivatisert OH-gruppe,
ellerc) for fremstilling av forbindelser med formel I hvor R <1> er
Y er -S02 -, -CO-, -C00- eller -C(R <6> )2 -, ogR<2> og X er som definert i krav 1, en forbindelse med formel IV
hvor Y er -S02 -, -CO-, -C00- eller -C(R <6> )2 -,R<3> er som definert i krav 1,
og L er Cl, Br, I eller en fri eller reaktiv, funksjonelt derivatisert OH-gruppe,
omsettes med en forbindelse med formel V
hvor R <1> er
ogR<2> og X er som definert i krav 1,
ellerd) for fremstilling av forbindelser med formel I hvor R <1>
er
Y er -CONH-,
ogR<2> og X er som definert i krav 1, en forbindelse med formel VI
hvorR<3> er som definert i krav 1, omsettes med en forbindelse med formel V
hvor R <1> er
ogR<2> og X er som definert i krav 1,
eller
e) for fremstilling av forbindelser med formel I hvor R <1> er -C(=NH)-NH2 ,
en cyangruppe omdannes til en amidinogruppe, og/eller
f) i en forbindelse med formel I omdannes ett eller flere radikalerR<1> ,R<2>o g/ellerR<3> til ett eller flere radikalerR<1> ,R<2>o g/ellerR<3> ,f. eks. ved
i) hydrolysering av en estergruppe til en karboksylgruppe,
ii) reduksjon av en nitrogruppe eller
iii) acylering av en aminogruppe,
og/eller
g) en base eller syre med formel I omdannes til et av dens salter.
4. Fremgangsmåte for fremstilling av farmasøytiske preparat,
karakterisert ved at en forbindelse med formel I ifølge krav 1 og/eller et av dens fysiologisk aksep table salter bringes i en egnet doseringsform sammen med minst ett fast, flytende eller halvflytende bærer- eller hjelpestoff.
5. Farmasøytisk preparat,
karakterisert ved et innhold av minst én forbindelse med formel I ifølge krav 1 og/eller et av dens fysiologisk akseptable salter.
6. Forbindelse for bekjempelse av tromboser, hjerteinfarkt, arteriosklerose, betennelser, apopleksi, angina pectoris, restenose etter angioplasti og claudiocatio intermittens,
karakterisert ved at den har formel I ifølge krav 1, og fysiologisk akseptable salter derav.
7. Medikamenter som inhibitorer for koagulasjonsfaktor Xa,
karakterisert ved at de har formel I ifølge krav 1, og deres fysiologisk akseptable salter.
8. Anvendelse av forbindelser med formel I ifølge krav 1 og/eller deres fysiologisk akseptable salter til fremstilling av et medikament.
9. Anvendelse av forbindelser med formel I ifølge krav 1 og/eller deres fysiologisk akseptable salter ved bekjempelse av tromboser, hjerteinfarkt, arteriosklerose, betennelser, apopleksi, angina pectoris, restenose etter angioplasti og claudiocatio intermittens.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19743435A DE19743435A1 (de) | 1997-10-01 | 1997-10-01 | Benzamidinderivate |
PCT/EP1998/005898 WO1999016751A1 (de) | 1997-10-01 | 1998-09-16 | Benzamidinderivate als faktor xa-inhibitoren |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20001687L true NO20001687L (no) | 2000-03-31 |
NO20001687D0 NO20001687D0 (no) | 2000-03-31 |
Family
ID=7844313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20001687A NO20001687D0 (no) | 1997-10-01 | 2000-03-31 | Benzamidinderivater som faktor Xa-inhibitorer |
Country Status (19)
Country | Link |
---|---|
US (1) | US6492368B1 (no) |
EP (1) | EP1025086B1 (no) |
JP (1) | JP2001518467A (no) |
KR (1) | KR20010024386A (no) |
CN (1) | CN1272107A (no) |
AR (1) | AR017164A1 (no) |
AT (1) | ATE243681T1 (no) |
AU (1) | AU736080B2 (no) |
BR (1) | BR9812699A (no) |
CA (1) | CA2305568A1 (no) |
DE (2) | DE19743435A1 (no) |
HU (1) | HUP0004306A3 (no) |
ID (1) | ID24430A (no) |
NO (1) | NO20001687D0 (no) |
PL (1) | PL339173A1 (no) |
RU (1) | RU2194044C2 (no) |
SK (1) | SK282799B6 (no) |
WO (1) | WO1999016751A1 (no) |
ZA (1) | ZA988937B (no) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69833036T2 (de) | 1997-09-30 | 2006-06-22 | Daiichi Pharmaceutical Co., Ltd. | Sulfonylderivate |
TR200003200T2 (tr) | 1998-05-02 | 2001-02-21 | Astrazeneca Ab | Faktör XA'yı önleyen heterosiklik türevler. |
GB9809349D0 (en) | 1998-05-02 | 1998-07-01 | Zeneca Ltd | Heterocyclic derivatives |
EP1104754A1 (en) * | 1998-08-11 | 2001-06-06 | Daiichi Pharmaceutical Co., Ltd. | Novel sulfonyl derivatives |
EP1088821A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
EP1829535A3 (en) * | 1999-10-27 | 2007-10-24 | Tanox, Inc. | Tissue factor antagonists and methods of use thereof |
KR20070049251A (ko) * | 1999-10-27 | 2007-05-10 | 타녹스 인코퍼레이티드 | 조직 인자 길항제 및 그의 사용 방법 |
DE10035927A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
DE10035928A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
EP1193267A1 (en) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases |
EP1193256A1 (en) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins |
EP1193268A1 (en) * | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
AU2002217999A1 (en) | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
DE10102322A1 (de) * | 2001-01-19 | 2002-07-25 | Merck Patent Gmbh | Phenylderivate |
DE10130718A1 (de) * | 2001-06-26 | 2003-01-02 | Merck Patent Gmbh | Kohlenhydratderivate |
DK1485353T3 (da) | 2002-03-13 | 2011-11-28 | Janssen Pharmaceutica Nv | Nye inhibitorer af histondeacetylase |
WO2003076422A1 (en) | 2002-03-13 | 2003-09-18 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
DK1569912T3 (en) | 2002-12-03 | 2015-06-29 | Pharmacyclics Inc | 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors. |
TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
EP1831164A1 (en) * | 2004-12-24 | 2007-09-12 | AstraZeneca AB | Heterocyclic compounds as ccr2b antagonists |
WO2007007588A1 (ja) * | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
US7825122B2 (en) * | 2005-12-14 | 2010-11-02 | Amgen Inc. | Diaza heterocyclic sulfonamide derivatives and their uses |
GB0525957D0 (en) | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
WO2007078335A2 (en) * | 2005-12-21 | 2007-07-12 | Decode Genetics, Ehf. | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
EP2054058B1 (en) | 2006-08-04 | 2016-11-09 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
WO2008148840A1 (en) * | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
WO2008148868A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
WO2008148851A1 (en) * | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
MX2010002258A (es) | 2007-08-27 | 2010-04-22 | Helicon Therapeutics Inc | Compuestos terapeuticos de isoxazol. |
PT2197841E (pt) * | 2007-09-07 | 2012-01-02 | Theravance Inc | Compostos contendo guanidina úteis como antagonistas do receptor muscarínico |
US8163898B2 (en) | 2007-09-21 | 2012-04-24 | Msd K. K. | 4-sulfonylpiperidine derivatives |
JP5579170B2 (ja) * | 2008-06-05 | 2014-08-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Dgat阻害剤とppar作動薬を含有する薬剤組み合わせ物 |
US20100152197A1 (en) * | 2008-12-15 | 2010-06-17 | Astrazeneca Ab | (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives |
MY161473A (en) | 2009-02-26 | 2017-04-14 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives |
WO2010118063A2 (en) | 2009-04-06 | 2010-10-14 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
WO2011002817A1 (en) | 2009-06-29 | 2011-01-06 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
DK2448581T3 (en) * | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
MX336022B (es) | 2010-12-21 | 2016-01-06 | Agios Pharmaceuticals Inc | Activadores de pkm2 bicíclicos. |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
WO2012151440A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
ES2675903T3 (es) | 2011-05-03 | 2018-07-13 | Agios Pharmaceuticals, Inc. | Activadores de piruvato quinasa para uso en terapia |
FR2976943B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
ES2753386T3 (es) * | 2013-03-13 | 2020-04-08 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer |
BR112015022226A2 (pt) * | 2013-03-14 | 2017-07-18 | Celtaxsys Inc | inibidores de leucotrieno a4 hidrolase |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
JP6412553B2 (ja) | 2013-03-21 | 2018-10-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Fasn阻害剤としてのピペラジン誘導体 |
MX2017016041A (es) | 2015-06-11 | 2018-04-24 | Agios Pharmaceuticals Inc | Metodos para usar activadores de piruvato cinasa. |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992008709A1 (de) | 1990-11-15 | 1992-05-29 | Pentapharm Ag | Meta-substituierte phenylalanin-derivate |
ZA928276B (en) | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
GB9208740D0 (en) | 1992-04-23 | 1992-06-10 | Glaxo Group Ltd | Chemical compounds |
DE4234295A1 (de) * | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
WO1997002245A1 (fr) * | 1995-07-06 | 1997-01-23 | Japan Tobacco Inc. | Derives de benzamidoxime et leur utilisation a des fins medicinales |
CA2197364A1 (en) * | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Phenol compound and process for preparing the same |
DE69835430T2 (de) * | 1997-05-30 | 2007-03-08 | Takeda Pharmaceutical Co. Ltd. | Sulfonamidderivate, ihre herstellung und verwendung |
-
1997
- 1997-10-01 DE DE19743435A patent/DE19743435A1/de not_active Withdrawn
-
1998
- 1998-09-16 AT AT98948982T patent/ATE243681T1/de not_active IP Right Cessation
- 1998-09-16 PL PL98339173A patent/PL339173A1/xx unknown
- 1998-09-16 DE DE59808842T patent/DE59808842D1/de not_active Expired - Fee Related
- 1998-09-16 US US09/509,729 patent/US6492368B1/en not_active Expired - Fee Related
- 1998-09-16 AU AU95407/98A patent/AU736080B2/en not_active Ceased
- 1998-09-16 RU RU2000110737/04A patent/RU2194044C2/ru not_active IP Right Cessation
- 1998-09-16 WO PCT/EP1998/005898 patent/WO1999016751A1/de not_active Application Discontinuation
- 1998-09-16 SK SK447-2000A patent/SK282799B6/sk unknown
- 1998-09-16 CA CA002305568A patent/CA2305568A1/en not_active Abandoned
- 1998-09-16 BR BR9812699-7A patent/BR9812699A/pt not_active IP Right Cessation
- 1998-09-16 KR KR1020007003536A patent/KR20010024386A/ko not_active Application Discontinuation
- 1998-09-16 ID IDW20000609A patent/ID24430A/id unknown
- 1998-09-16 JP JP2000513837A patent/JP2001518467A/ja active Pending
- 1998-09-16 EP EP98948982A patent/EP1025086B1/de not_active Expired - Lifetime
- 1998-09-16 CN CN98809650A patent/CN1272107A/zh active Pending
- 1998-09-16 HU HU0004306A patent/HUP0004306A3/hu unknown
- 1998-09-29 AR ARP980104841A patent/AR017164A1/es not_active Application Discontinuation
- 1998-09-30 ZA ZA988937A patent/ZA988937B/xx unknown
-
2000
- 2000-03-31 NO NO20001687A patent/NO20001687D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA988937B (en) | 1999-03-31 |
JP2001518467A (ja) | 2001-10-16 |
AR017164A1 (es) | 2001-08-22 |
EP1025086B1 (de) | 2003-06-25 |
DE59808842D1 (de) | 2003-07-31 |
RU2194044C2 (ru) | 2002-12-10 |
CN1272107A (zh) | 2000-11-01 |
WO1999016751A1 (de) | 1999-04-08 |
US6492368B1 (en) | 2002-12-10 |
BR9812699A (pt) | 2000-08-22 |
SK282799B6 (sk) | 2002-12-03 |
ATE243681T1 (de) | 2003-07-15 |
AU736080B2 (en) | 2001-07-26 |
CA2305568A1 (en) | 1999-04-08 |
NO20001687D0 (no) | 2000-03-31 |
DE19743435A1 (de) | 1999-04-08 |
PL339173A1 (en) | 2000-12-04 |
ID24430A (id) | 2000-07-20 |
SK4472000A3 (en) | 2000-11-07 |
HUP0004306A2 (hu) | 2001-11-28 |
AU9540798A (en) | 1999-04-23 |
KR20010024386A (ko) | 2001-03-26 |
HUP0004306A3 (en) | 2001-12-28 |
EP1025086A1 (de) | 2000-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20001687L (no) | Benzamidinderivater som faktor Xa-inhibitorer | |
SK8572000A3 (en) | Benzamine derivatives | |
US20040038858A1 (en) | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | |
JP4732757B2 (ja) | カルボキサミド | |
CA2364908A1 (en) | Pyrazol-3-one derivatives | |
AU2004205354B2 (en) | Carboxamide derivatives and their use as factor Xa inhibitors | |
US7183277B2 (en) | Carboxylic acid amides | |
MXPA00003094A (en) | Benzamidine derivatives as factor xa inhibitors | |
CZ20001183A3 (cs) | Derivát benzamidinu jako inhibitor faktoru XA, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje | |
CZ20002126A3 (cs) | Řešení se týká nosného tělesa (1) pro uspořádání elektrických kontaktů, které obsahuje elektricky nevodivé základní těleso, ve kterémjsou uspořádány elektrické kontakty (3). Nosné těleso (1) má modulovou konstrukci, sestávající z jednotlivých samostatných prvků (2,4), které mohou být spolu vzájemně sestaveny a spojeny. Jednotlivé samostatné prvky (2,4) mohou nebo nemusejí být opatřeny kontakty (3). | |
NO20025740L (no) | Karbaminsyreestere som inhibitorer for faktor Xa | |
US20030171579A1 (en) | Urethane derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |